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INTRODUCTION 
              Cancer is a general term used to refer to a condition where the body cells begin to grow 
and reproduce in an uncontrollable way. These cells can then invade and destroy healthy tissue, 
including organs. Cancer sometimes begins in one part of the body before spreading to other 
parts. Cancer is a common condition and a serious health problem. More than one in three people 
will develop some form of cancer during their lifetime. There are hundreds of different types of 
cancer. In 2012 about 14.1 million new cases of cancer occurred globally. It caused about 8.2 
million deaths or 14.6% of human deaths. The most common types of cancer in males are lung 
cancer, prostate cancer, colorectal cancer and stomach cancer. In females, the most common 
types are breast cancer, colorectal cancer, lung cancer and cervical cancer.                                                                                                                                                                                                                                                             
Treatment for cancer will depend on many factors. Such as the stage and location of the disease 
it includes the surgery, chemotherapy, radiation therapy. Possible sign and symptoms include a 
lump, abnormal bleeding, prolonged cough, unexplained weight loss and a change in bowel 
movements. While these symptoms may indicate cancer, they may have other causes over 100 
types of cancers affect humans. Cancers harms the body when altered cells divide uncontrollably 
to form lumps or masses of tissue called tumors. Tumors can grow and interfere with the 
digestive, nervous and circulatory system. 
Tumors form when two things occur 
 A cancerous cell manages to move throughout the body using the blood or lymphatic 
systems, destroying healthy tissue in a process called invasion. 
 That cell manages to divide and grow, making new blood vessels to feed itself in a 
process called angiogenesis. 
Colon cancer is one of the three most common cancers diagnosed in the United States and 
includes cancers of the colon and rectum. In 2007, approximately 1,53,760 new cases were 
diagnosed and an estimated 52,180 deaths occurred, making colon cancer the second leading 
cause of cancer-related deaths in the United States. Patient prognosis is determined primarily by 
the extent or stage of disease, with most patients with early-stage disease being cured. Treatment 
of colon cancer includes surgery, radiation, chemotherapy, and new targeted molecular therapies. 
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Colon specific delivery: 
The colon drug delivery has a number of important implications in the field of pharmacotherapy. 
Various diseases including Inflammatory Bowel Diseases (IBD) can be effectively treated by the 
local delivery of drugs to the large intestine. The treatment of IBD with anti-inflammatory drugs 
is particularly improved by their local delivery to the bowel. By this technique, absorption of 
drugs from the stomach and small intestine can be minimized until the drug reaches the large 
intestine. Various drug delivery systems have been designed that deliver the drugs quantitatively 
to the large bowel and subsequently to trigger the release of active drug. The treatment of large 
intestine disorders, such as Crohn‘s disease, irritable bowel syndrome, colitis, colon cancer and 
local infectious disease where a high concentration of active drug is needed, can be improved by 
colon specific drug delivery systems employing various mechanism of release. Moreover, the 
introduction of several peptide-based drugs in the recent past has triggered the demand to explore 
alternative non-parenteral routes for their delivery. (Manish p patel et al) 
              Figure 1: COLON RECTAL CANCER 
     
The site-specific delivery of the drugs to the target receptor sites has the potential to reduce the 
side effects and improve the pharmacological response. However, for successful colonic drug 
delivery, many physiological barriers must be overcome, the major one being absorption or 
degradation of the active drug in the upper part of the GI tract. The disease state can also 
potentially alter the delivery and absorption characteristics of drug from the colon. 
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The colon drug targeting is also exploited for systemic delivery of active drugs. Most of the 
peptide and protein drugs are unstable in the stomach and upper part of intestine. Apart from 
stability problems, peptides are not well absorbed from the lumen of the GIT due to their large 
molecular size and highly sensitive to brush border peptidase activity. Comparatively, proteolytic 
activity of colon mucosa is much less than that observed in the small intestine. Colon specific 
drug delivery systems protect peptide drugs from hydrolysis and enzymatic degradation in the 
duodenum and jejunum, and eventually release drugs in the ileum or colon, which leads to 
greater systemic bioavailability. The specific release in the colon also affects a time delay 
between administration and onset of action, which can be useful for diseases with various 
degrees of severity, such as asthma and arthritis. 
Various colon specific drug delivery systems are being developed, by taking advantage of the 
luminal pH in the ileum and the microbial enzymes in the colon, such as pectinase, amylase, 
dextranase, glycosidase and azoreductase. 
                         Table 1: COLON TARGETING DISEASE, DRUGS AND SITES: 
 
           Target sites 
 
    Diseases conditions 
 
Drugs and active agents 
 
      Topical action 
Inflammatory Bowel Disease, 
Irritable bowel disease and Crohn‘s 
disease. 
Hydrocortisone, Budenoside, 
Prednisolonr, Sulfasalazine, 
Olsalazine, Mesalazine and 
Balsalazide. 
      Local action 1)Chronicpancreatitis, 
pancreatactomy and cystic fibrosis. 
2)Colorectal cancer 
Digestive enzyme supplements. 
 
5-Flourouracil 
 
 
1)To prevent gastric irritation 
2)To prevent first pass metabolism 
of orally ingested drugs 
3)Oral delivery of peptides 
4)Oral delivery of vaccines 
NSAIDs 
Steroids 
 
Insulin 
Typhoid 
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ANATOMIC AND PHYSIOLOGICAL CONSIDERATIONS: 
 In GIT, large intestine starts from the ileocecal junction to the anus with a length of about 1.5m 
(adults) and is divided in to three parts, viz., colon, rectum and anal canal. 
Colon: 
The colon consists of cecum, colon ascendens, colon transvesale, colon descendens and sigmoid 
colon. Colon is made up of four layers, serosa, muscularis externa, sub mucosa and mucosa. 
 Figure 2:  ANATOMY OF COLON AND RECTUM 
                               
             
The serosa is the exterior coat of the large intestine and consists of areolar tissue that is covered 
by a single layer of squamous mesothelial cells. 
The muscularis externa is composed of the major muscular coat of inner circular layer of fibers 
that surrounds the bowel and an outer longitudinal layer. Colonic longitudinal muscle fibers are 
composed of three flat long bands called taeniacoli, which is shorter than other coats of the colon 
and hence results in wall contractions and formation of haustra. 
The sub mucosa is the layer of connective tissue that lies immediately beneath the mucosa. 
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The mucosa lines the lumen of the colon and is divided into epithelium, laminapropria and 
muscularis mucosae. The mucosa has a layer of smooth muscles and seperates the sub mucosa 
from the lamina propria, which supports the epithelium. The blood capillaries and lymphatic 
vessels supply bio fluids to lamina propria. (Cherukuri Sowmya et al) 
 Cecum(proximal right colon) 
6 x 9 cm pouch covered with peritoneum 
 Appendix 
A vermiform diverticulum located in the lower cecum 
 Ascending colon 
20-25 cm long, located behind the peritoneum 
 Hepatic flexure 
Lies under right lobe of liver 
 Transverse colon 
Lies anterior in abdomen, attached to gastro colic ligament 
 Splenic flexure 
Near tail of pancreas and spleen 
 Descending colon 
10-15 cm long, located behind the peritoneum 
 Sigmoid colon 
Loop extending distally from border of left posterior major psoas muscle 
 Recto sigmoid segment 
Between 10 and 15 cm from anal verge 
The adult colon is lined by at least eight distinct epithelial cell types, viz. Columnar and 
absorptive cells, deep crypt secretary cells, vacuolated cells, micro fold or ‗M‘ cells, 
undifferentiated crypt cells, multi vesicular or caveolated cells, and variety of entero endocrine 
cells. They constitute a structural and functional barrier protecting the internal milieu from direct 
contact with luminal components such as the indigenous bacterial flora or exogenously 
introduced antigens or viruses. The villi of the columnar cells contribute to the surface area of 
the colon. Apart from stomach, the GIT has normal bacterial flora, which inhibits the growth of 
other organisms. Some species of normal micro flora produce short chain fatty acids or 
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antibiotics such as ―clostin‖,which prevents the growth of pathogens by competing with them for 
nutrients. The mucous lining of GIT forms a barrier against bacterial invasion of the gut wall. 
Antibodies Ig A and Ig G enhance the phagocytosis of GI bacteria. 
Rectum: 
12 cm long; upper third covered by peritoneum; no peritoneum on lower third which is also 
called the rectal ampulla. About 10 cm of the rectum lies below the lower edge of the peritoneum 
(below the peritoneal reflection), outside the peritoneal cavity. 
Anal canal: 
Most distal 4-5 cm to anal verge. 
Colorectal polyps: 
Colorectal cancer most often begins as a polyp, a noncancerous growth that may develop on the 
inner wall of the colon or rectum as people get older. If not treated or removed, a polyp can 
become a potentially life-threatening cancer. Recognizing and removing precancerous polyps 
can prevent colorectal cancer. There are several forms of polyps. Adenomatous polyps, or 
adenomas, are growths that may become cancerous and can be found with a colonoscopy. Polyps 
are most easily found during colonoscopy because they usually bulge into the colon, forming a 
mound on the wall of the colon that can be found by the doctor. About 10% of colon polyps are 
flat and hard to find with a colonoscopy unless a dye is used to highlight them. These flat polyps 
have a high risk of becoming cancerous, regardless of their size. Hyperplastic polyps may also 
develop in the colon and rectum. They are not considered precancerous. 
Risk factors for colorectal cancer include: 
 Ulcerative colitis, sometimes called pan ulcerative colitis. 
 Familial or multiple polyposis: a disease occurring in some families that consists of 
multiple adenomatous polyps of the colon which have high malignant potential. Also 
called familial polyposis colonae, polyposis coli, familial intestinal polyposis, hereditary 
gastrointestinal polyposis, multiple familial polyposis, Gardner's syndrome, Peutz-
Jaegher's syndrome, Canada - Cronkhite syndrome, or Turcot syndrome. 
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 Crohn's disease: a benign chronic granulomatous inflammatory disease of any or all parts 
of the colon. 
 Diet that is low in fiber, causing digestion to be slowed and transit time through the 
bowel to be increased. 
 Patient history of colon or rectal cancer. 
 Patient history of colon or rectal polyps. 
 Family history of colorectal cancer or female genital cancer. 
Signs and symptoms: 
The early signs of colorectal cancer can mimic symptoms caused by other gastrointestinal 
illnesses, such as influenza, ulcers, and colitis (an inflammation of the colon). If any of the 
following symptoms last more than two weeks, however, it is important to see a physician for an 
evaluation: 
 Unexplained persistent diarrhea or constipation. 
 Blood in or on the stool (can be bright red or very dark). 
 Narrower stools than usual. 
 Unexplained iron deficiency anemia. 
 Intermittent abdominal pain. 
The following symptoms can be signs of rectal cancer:  
 Blood in the stool. 
 Diarrhea. 
 A sense of bowel movement urgency. 
 Feeling of inadequate emptying of bowel. 
 Excessive straining to have a bowel movement without passing of stools. 
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Layers of Bowel Wall  
 Lumen (interior surface of colon "tube") 
 Mucosa 
 Surface epithelium 
 Lamina propria or basement membrane—dividing line between in situ and invasive lesions 
 Muscularis mucosae 
 Sub mucosa—lymphatics; potential for metastases increases 
 Muscularis propria 
 Circular layer 
 Longitudinal layer—in three bands called taenia coli 
 Sub serosa—sometimes called pericolic fat or sub serosal fat 
 Serosa—present on ascending, transverse, sigmoid only (also called the visceral peritoneum) 
 Retroperitoneal fat (also called pericolic fat) 
 Mesenteric fat (also called pericolic fat) 
     Figure 3: LAYERS OF BOWEL WALL 
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Regional Lymph Nodes: 
There are between 100 and 150 lymph nodes in the mesentery of the colon. Regional 
lymph nodes are the nodes along the colon, plus the nodes along the major arteries that supply 
blood to that particular colon segment. Lymph nodes along a "named vascular trunk" are those 
along a vein or artery that carries blood to a specific part of the colon, for example, the inferior 
and superior mesenteric arteries, sigmoidal artery, left or right colic artery.                   
Table 2:  REGIONAL LYMPH NODES 
Segment Regional Lymph Nodes 
Cecum Pericolic, anterior cecal, posterior cecal, ileocolic, right colic 
Ascending colon Pericolic, ileocolic, right colic, middle colic 
Hepatic flexure Pericolic, middle colic, right colic 
Transverse colon Pericolic, middle colic 
Splenic flexure Pericolic, middle colic, left colic, inferior mesenteric 
Descending colon Pericolic, left colic, inferior mesenteric, sigmoid 
Sigmoid colon 
Pericolic, inferior mesenteric, superior rectal, superior hemorrhoidal, 
sigmoidal, sigmoid mesenteric 
Rectosigmoid 
Perirectal, left colic, sigmoid mesenteric, sigmoidal, inferior mesenteric, 
superior rectal, superior hemorrhoidal, middle hemorrhoidal 
Rectum 
Perirectal, sigmoid mesenteric, inferior mesenteric, lateral sacral, 
presacral, internal iliac, sacral promontory superior hemorrhoidal, 
inferior hemorrhoidal 
Anus 
Perirectal, anorectal, superficial inguinal, internal iliac, hypogastric, 
femoral, lateral sacral 
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Figure 4: REGIONAL LYMPH NODES 
 
Types of cancer in the colon and rectum: 
Here is an overview of the types of cancer that can start in the colon and rectum: 
 Adenocarcinoma. The most common type of colorectal cancer. More than 95% of 
colorectal cancers are adenocarcinoma. This cancer starts in the lining of internal 
organs. The tumors start in gland cells that release, or secrete, fluids. 
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Other types of cancer that can start in the colon or rectum are much less common: 
 Gastro intestinal stromal tumor (GIST). These tumors start in special cells in the wall of 
the digestive tract. They may be found anywhere in the digestive tract. But they rarely 
appear in the colon. They may be benign, or not cancer, at first. But many do turn into 
cancer. 
 Lymphoma. This cancer starts in a type of immune cell called a lymphocyte. Lymphomas 
often start in bean-sized groups of lymphocytes, called lymph nodes. But they can also 
start in the colon, rectum, or other organs. 
 Carcinoid. This cancer starts in special hormone-making cells in the intestine. 
 Sarcoma. These tumors start in blood vessels, muscle, or connective tissue in the colon 
and rectum wall.  
Factors governing the colon drug delivery: 
Physiological Factors:  
1. Gastro intestinal transit: 
            The drug delivery systems first enter in to stomach and intestine via mouth and then 
reach colon. The nature and pH of gastric secretions and gastric mucosa influence the drug 
release and absorption. In order to successfully reach colon in an intact form, the drug delivery 
systems should surpass the barriers in the stomach and small intestine. 
In fasted state, the motility proceeds through four phases occurring in stomach and small 
intestine that span over a period of 2-3h. Phase 1 is a quiescent period of 40-60min. Phase 2 
consists of intermittent contractions for a period of 40-60min. Phase 3 is a period of intense 
contractions sweeping material out of the stomach and down the small intestine followed by 
Phase 4 with contractions dissipating. The feeding state affects the normal pattern by irregular 
contractile activity. (Kothawade P D et al). 
2. Small intestinal transit: 
Normally, the small intestinal transit is not influenced by the physical state, size of the 
dosage form and the presence of food in the stomach. The mean transit time of the dosage form 
is about 3-4h to reach the ileocecal junction and the time period is consistent. The dosage form is 
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exposed to enzymes such as esterase, lipase, amylase, protease, nuclease and brush border 
enzymes present in the small intestine. The release of drugs from the pro drug based systems and 
stability of peptides can be affected by bacterial contents in the ileum. 
3. Colonic transit: 
              The bioavailability of drugs, released from the dosage forms can be highly influenced 
by the colonic transit time. Unlike small intestine, colonic transit time shows considerable 
variability. Various factors like gender and size of the dosage form, and physiological conditions 
such as stress, presence of food and disease state influence the colonic transit time. Small 
particles and solutions pass slowly through proximal colon and in human beings, men show 
shorter transit time than women. Small variation in dietary fibre and age does not alter the transit 
time, significantly. The colonic transit time of a capsule in adults is 20-35 h,the transit rate being 
independent of capsule density and volume. Improved residence time with subsequent longer 
transit time and the contact of dosage form with micro flora in colon may govern release and 
absorption of drug from dosage form. 
4. Gastric emptying: 
Generally, in fasted state, gastric emptying is fastest and most consistent.                         
Emptying completes from 5-10 min up to 2 hours, depending on phase of the stomach at the time 
of drug administration. Gastric emptying can be considerably slowed by the fed state. For drug 
delivery to the systemic vasculature, small transit time in stomach to reduce random distribution 
of particulate drug through intestine is preferable. The residence time in the stomach is important 
for single unit sustained release systems like tablets, which are designed to deliver drug in large 
intestine. Such systems may release the drug at a distant locus from the colon. (S P Vyas et al) 
5. Stomach and intestinal pH: 
               Generally, the release and absorption of orally administered drugs are influenced by the 
gastrointestinal pH. The pH gradient in the GIT is not in an increasing order. In stomach the pH 
is 1.5-2 and 2-6 in fasted and fed conditions, respectively. The acidic pH is responsible for the 
degradation of various pH sensitive drugs and enteric coating may prevent it. In small intestine, 
the pH increases slightly from 6.6-7.5 and decreases to 6.4 in right colon. 
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                The pH of mid colon and left colon is 6.6 and 7.0, respectively. Since there is minimal 
variation in the pH from ileum to colon, apparently pH dependent polymer drug delivery may not 
be much selective. However, possible exploitation of pH variation in GIT leads to successful 
development of various colon specific drug delivery systems. 
6. Colonic micro flora and enzymes: 
              The human alimentary canal is highly populated with bacteria and other micro flora at 
both ends, that is the oral cavity and the colon or rectum. Microorganisms of the oral cavity, 
normally do not affect oral drug delivery systems, however, gut micro flora of the colon offers a 
number of implications in health. The concentration of gut micro florarises considerably high 
levels in the colon. 
               The enzyme catalyzed metabolic reactions carried out by the enzymes and secretary 
products released from the micro flora can be used to deliver drugs selectively to colon. The 
enzymes which trigger the release of drugs in the colon are glycosidase and glucuronidases. 
7. Colonic absorption:  
               The surface area of the colon is much less compared to small intestine, and hence not 
ideally suited for absorption. The colon is considered for drug delivery because the environment 
is devoid of endogenous digestive enzymes other than from microbial origin and the residence 
time of colon can be as long as 10-24 h. Little mixing in the colon makes it possible to create 
local environments with optimal absorption conditions. The higher viscosity of colonic content 
delays the diffusion of drug from the lumen to mucosa. The absorption is influenced by the 
transport of water, electrolytes and ammonia across the mucosa, and it is more in the proximal 
colon than the distal colon. 
         Drug molecules pass from the apical to baso lateral surface of the epithelial cells by 
 Passing through colonocytes. 
 Passing between adjacent colonocytes. 
Absorption enhancers facilitate effective absorption through various mechanisms 
 Disruption of the intra cellular occluding junction complex opens the para cellular 
route. 
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 Modification of epithelial permeability by denaturing membrane proteins. 
 Modification of lipid protein interactions and disruption of the integrity of lipid 
barrier by colonic enterocytes. 
Pharmaceutical Factors: 
1. Drug candidates: 
               Drugs, which show poor absorption from the stomach or intestine including peptide 
drugs, are most suitable for colon-specific drug delivery systems. The drugs used in the treatment 
of IBD, ulcerative colitis, diarrhea and colon cancer. 
2. Drug carriers:  
               The selection of carrier for particular drug candidate depends on the physiochemical 
nature of the drug as well as the disease. The factors such as chemical nature, stability and 
partition coefficient of the drug and the type of absorption enhancer chosen influence the carrier 
selection. Moreover, the choice of drug carrier depends on the functional groups of the drug 
molecule. 
CAPECITABINE: 
 Capecitabine is a pyrimidine analogue used as an antineoplastic agent to treat metastatic 
and advanced forms of breast and colon cancer. It is an oral pro drug of 5-FU that also is 
effective in the adjuvant setting and is being evaluated as a replacement for 5-FU for patient 
convenience and safety reasons. 5-Fluorouracil-based chemotherapy is the standard of care for 
the adjuvant treatment of colorectal cancer either as a single agent or more commonly, in 
combination with other agents. Capecitabine was approved for use as an anticancer agent in the 
United States in 1998 and is currently an important component of several cancer 
chemotherapeutic regimens. Current indications include advanced, metastatic breast cancer and 
colorectal cancers, usually after failure of first line therapies. Once swallowed, Capecitabine is 
rapidly and completely absorbed as an intact molecule through the gastrointestinal mucosa. 
Capecitabine is not intrinsically cytotoxic, and  undergoes a three-step conversion to 5-FU. The 
first stage is mediated by carboxyl esterase in the liver, and the second step is governed by 
cytidine deaminase in liver/tumor tissue. The final conversation step, which results in the 
generation of 5-FU,is being phosphorylation by thymidine phosphorylase (TP). TP levels are 
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reported to be higher in tumor cells than in normal tissues; therefore, the systemic exposure of 
active drug is minimized, and tumor concentrations of the active drug are optimized. TP is 
identical in structure and function to tumor – associated angiogenic factor and platelet- derived 
endothelial cell growth factor. It includes neovascularization and prevents tumor cells from 
entering apoptosis. TP expression correlates with fat malignant growth aggressive invasion 
potential, and poor patient prognosis. TP activation may, therefore, enable capecitabine provides 
a clear rationale for combining capecitabine with anti-tumor agents that further up regulate TP in 
tumor tissue. Fluorouracil is further metabolized to two active metabolites, 5-fluoro-2-
deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP), within normal 
and tumour cells. FdUMP inhibits DNA synthesis by reducing normal thymidine production, 
while FUTP inhibits RNA and protein synthesis by competing with uridine tri phosphate. The 
active moiety of capecitabine, fluorouracil, is cell cycle phase-specific (S- phase). 
NANOPARTICLES:              
 The prefix ―nano‖ comes from the ancient Greek vavoc through the Latin nanus 
meaning very small. Nanotechnology defined as design characterization, production and 
applications of structures, devices and systems by controlling shape and size at nanometer scale. 
According to International System of Units (SI) nanotechnology is typically measured in 
nanometers scale of 1 billionth of a meter (1nm corresponding to 10-9 m) referred as the ―tiny 
science‖. At this small size molecules and atoms work differently, behave as a whole unit in 
terms of its properties and transport, provide a variety of advantages. Nanoparticles are defined 
as particulate dispersions or solid particles with a size in the range of 10-1000 nm. The drug is 
dissolved, entrapped, encapsulated or attached to a nanoparticle matrix. The term nanoparticle is 
a combined name for both nanosphares and nanocapsules. Drug is confined to a cavity 
surrounded by a unique polymer membrane called nanocapsules, while nanospheres are matrix 
systems in which the drug is physically and uniformly dispersed. Where a conventional 
technique reaches their limits, nanotechnology provides opportunities for the medical 
applications. Depending upon the method of preparation, nanoparticles, nanospheres or 
nanocapsules can be obtained. Advantages in nanoparticle drug delivery, particularly at the 
systemic level, include longer circulation half-lives, improved pharmacokinetics and reduced 
side effects. In cancer treatments, nanoparticles can further rely on the enhanced permeability 
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and retention effect caused by leaky tumor vasculatures for better drug accumulation at the tumor 
sites. 
 Nanoparticles were first developed for the parenteral route; more recently, they have 
also been studied as oral delivery vehicles. Clearly, a wide variety of drugs can be delivered via 
the oral route using polymeric nano particulate carriers and much of the research has focused on 
the absorption enhancement of peptides, proteins, and vaccine antigens. Generally conventional 
preparations like solutions, suspension from certain limitations like higher dose requirement due 
to low bioavailability which often associated with the first pass effect with intolerance and 
instability. They are associated with fluctuation in plasma drug levels and do not provide 
sustained effect. Hence, some novel carriers are need of the hour, which could meet ideal 
requirement of drug delivery systems. Therefore the nanoparticles are associated with other nano 
size related property that differs significantly from those observed in fine particles. (Nagavarma 
B V N et al) 
  Nanoparticles play an important role in a number of these applications. Nanoparticles 
which in general terms are defined as engineered structures with diameters of < 100nm are 
devices and systems produced by chemical and physical processes having specific properties. 
The reason why nanoparticles are attractive for such purposes is based on their important and 
unique features, such as their surface to mass ratio, which is much larger than that of other 
particles and materials, allowing for catalytic promotion of reactions, as well as their ability to 
adsorb and carry other compounds. The reactivity of the surface originates from quantum 
phenomena and can make nanoparticles unpredictable since, immediately after generation; 
nanoparticles may have their surface modified depending on the presence of reactants and 
adsorbing compounds, which may instantaneously change with changing compounds and 
thermodynamic conditions. Therefore, on one hand, nanoparticles have a large (functional) 
surface which is able to bind, adsorb and carry other compounds such as drugs, probes and 
proteins. On the other hand, nanoparticles have a surface that might be chemically more reactive 
compared to their fine analogues. The ideal requirement for designing nano particulate delivery 
system are to effectively control the particle size, surface properties, enhance solubility and 
release of pharmacologically active ingredients in order to achieve the site specific delivery at 
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pre-determined rate. Hence the polymeric nanoparticle effects stability of drugs and possess 
useful control release properties. 
Advantages of Nanoparticles: 
A nanoparticle offers numerous advantages in drug delivery system. These advantages include, 
but are not limited:   
 Nanoparticles have much significant advantage over conventional and traditional 
drug delivery system. 
 Nanoparticles are control and sustain release form at the site of localization; they alter 
organ distribution of drug compound. They enhance drug circulation in blood, 
bioavailability, and therapeutic efficacy and reduce side effects. 
 Nanoparticles can be administered by various routes including oral, nasal, parenteral, 
intra-ocular etc.  
 In the tiny areas of body nanoparticles shows better drug delivery as compare to other 
dosage form and target to a particular cell type or receptor.  
 Due to small particle size a nanoparticle overcome resistance by physiological 
barriers in the body and easily penetrates to cell walls, blood vessels, stomach 
epithelium and blood–brain barrier.  
 Nanoparticle enhances the aqueous solubility of poorly soluble drug, which improves 
bioavailability of drug.                                 
 As targeted drug carrier nanoparticles reduce drug toxicity and enhance efficient drug 
distribution. 
 By using polymers drug release form nanoparticles can be modified which makes 
polymeric nanoparticle an ideal drug delivery system for cancer therapy, vaccines, 
contraceptives and antibiotics. 
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POLYMERS USED IN THE PREPARATION OF NANOPARTICLES:  
The polymers should be compatible with the body in the terms of adaptability (non- 
toxicity) and (non-antigenicity) and should be biodegradable and biocompatible. 
The most commonly used natural polymers in preparation of polymeric nanoparticles are     
 Chitosan 
 Gelatin 
 Sodium alginate 
 Albumin 
There are many synthetic polymers like    
 Poly lactides (PLA)   
 Poly glycolides (PGA)   
 Poly (lactide co-glycolides) (PLGA)   
 Poly anhydrides 
 Poly orthoesters 
 Poly cyanoacrylates 
 Poly caprolactone 
 Poly glutamic acid   
 Poly malic acid   
 Poly (N-vinyl pyrrolidone) 
METHODS OF PREPARATION OF NANOPARTICLES: 
               In the preparation of nanoparticles different types of matrix material are used such as 
polysaccharides, synthetic polymer and proteins. Various factors are involved in selection of 
matrix material to be used in preparations which are (Abhishek Garg et al) 
(i) Required nanoparticle size. 
(ii) Permeability and surface charge of nanoparticle.  
(iii) Level of biodegradability and biocompatibility must be optimum. 
(iv) Material must not be toxic.  
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(v) Solubility profile and stability of drug should not be affected. 
(vi) It should show desired drug release profile. 
(vii) Must not be immunogenic.   
Following are methods which are used in formulation of nanoparticles     
                      1. Dispersion of preformed polymers.  
                      2. Polymerization method.   
                      3. Coacervation or ionic gelatin method.  
                      4. Supercritical fluid technology 
1. Dispersion of preformed polymers: 
Solvent evaporation method:  
In this method, there is conventional formation of o/w emulsion between a partially water 
miscible solvent containing the polymer and the drug, and an aqueous phase containing the 
stabilizer. In this polymer is dissolved in an organic solvent such as dichloromethane, chloroform 
or ethyl acetate. Oil in water (o/w) emulsion is prepared by emulsification of drug and polymer 
mixture in aqueous solution which contain emulsifying agent, which result in formation of stable 
emulsion. After that by using pressure reduction method or continuous stirring, organic solvent is 
evaporated. The homogenizer speed, nature and stabilizer concentration along with the property 
of polymer effect size of nanoparticle. Usually high speed homogenizer or ultra-sonication had 
been used to reduce the size of nanoparticle to an optimum size. Spontaneous emulsification or 
solvent diffusion method also known as modified version of solvent evaporation method. In this 
method, two phase solvent is used, one is water miscible and other is water immiscible i.e. 
organic in nature which act as oil phase. In this method interfacial turbulence is created, by 
immediate diffusion between two solvents (which are differing in phase) which lead to the 
formation of small particles. A reduction in particle size can be gained by increasing the 
concentration of water miscible solvent both the above described method can be used for 
preparation of hydrophilic and hydrophobic drugs.    
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Salting out: 
             It is one of commonly used method used for preparation of nanoparticle. This method 
involves the mixing of saturated aqueous solution of polyvinyl alcohol (PVA) into an acetone 
solution of the polymer under magnetic stirring resulting in the formation of o/w emulsion. The 
precipitation of the polymer occurs when sufficient amount of water is added to external phase to 
allow complete diffusion of the acetone from internal phase into aqueous phase.   
2. Polymerization method: 
Polymerization of monomers in an aqueous solution forms the basis of this method. Two 
different techniques are used for the preparation in aqueous solution.    
              a) Emulsion polymerization: This method involves emulsification of monomer in non-
solvent phase. 
              b) Dispersion polymerization: This method involves dispersion of monomer in non-
solvent phase.   
              Incorporation of drug in nanoparticle can be achieved either by dissolving the drug in 
polymerization medium or by adsorption onto nanoparticle. Suspension of nanoparticles is 
formed, which contain surfactants and stabilizers that are used in polymerization which has to be 
removed by method like ultracentrifugation or by suspending them in isotonic medium which is 
free of surfactant. Poly butyl cyanoacrylate or poly (alkyl cyanoacrylate) nanoparticles are been 
prepared by this method. The polymer particle size had been affected by concentration of 
stabilizer and surfactant involved in preparation.  
3. Production of nanoparticles using supercritical fluid technology: 
Various conventional approaches like solvent diffusion, solvent extraction-evaporation 
and organic phase separation require the use of organic solvent are hazardous to the environment 
as well as the physiological systems. Supercritical fluid technology thus has been invested as an 
alternative to prepare biodegradable micro and nanoparticles. Solvent which remain fluid in a 
single phase regardless of pressure above critical temperature are known as supercritical fluid. 
Super critical CO2 is the most widely used supercritical fluid. The most common processing 
techniques involves supercritical fluids are Supercritical Anti Solvent (SAS) and Rapid 
Expansion of Critical Solution (RESS).  
INTRODUCTION 
 
DEPARTMENT OF PHARMACEUTICS, PSG COLLEGE OF PHARMACY Page 21 
 
4. Coacervation or ionic gelation method: 
Chitosan nanoparticles were prepared on the basis of the ionic gelation method. At the 
initial step, defined concentrations of TPP aqueous solution was prepared and added drop by 
drop to CS solution, which was prepared in 1% acetic acid (v/v); the solution was stirred at 400 - 
600 rpm. Different CS/TPP ratios were prepared to determine an appropriate formulation with 
optimum properties. Particle size distribution of the prepared colloidal suspensions was 
determined by the light scattering method using a particle size analyzer. Moreover, the effect of 
sonication on mean particle size was evaluated. (Amir Dustgani et al) 
EVALUATION OF NANOPARTICLES: 
Drug content:  
              Accurately weighed powder sample was transferred into a volumetric flask and made up 
to volume with distilled water. The solution was suitably diluted with distilled water and 
absorbance was measured using UV-visible spectrophotometer. 
Entrapment Efficiency: 
The procedure of entrapment efficiency was to determine the drug entrapped into the 
copolymer. The prepared formulations were centrifuged in 2 ml eppendorf tube at 15000 rpm for 
about 30 minutes. Then the samples were separated into supernatant and precipitated one. The 
precipitated samples were re dispersed by using buffers and re centrifuged for 3-4 times to get 
entrapped drug alone. The samples were then subjected for the analysis of UV visible 
spectrophotometer. 
            %EE = Total amount of drug - Entrapped drug / Total amount of drug X100 
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APPROACHES FOR COLON DRUG DELIVERY SYSTEM: 
 pH sensitive system 
 Time controlled or Time dependent system 
 Microbially triggered system 
 Targeted prodrug design 
 Pressure controlled system 
 Osmotically controlled system 
 CODESTM 
CODESTM: 
 CODESTM is a combined approach of pH dependent and microbially 
triggered CDDS. It has been developed by utilizing a unique mechanism involving lactulose, 
which acts as a trigger for site specific drug release in the colon. The system consists of a 
traditional tablet core containing lactulose, which is over coated with and acid soluble material, 
and then subsequently over coated with an enteric material. The premise of the technology is that 
the enteric coating protects the tablet while it is located in the stomach and then dissolves quickly 
following gastric emptying. The acid soluble material coating then protects the preparation as it 
passes through the alkaline pH of the small intestine. Once the tablet arrives in the colon, the 
bacteria enzymatically degrade the polysaccharide (lactulose) into organic acid. This lowers the 
pH surrounding the system sufficient to affect the dissolution of the acid soluble coating and 
subsequent drug release. (Prasanth V. V et al)     
  
 
 
 
 
 
 
INTRODUCTION 
 
DEPARTMENT OF PHARMACEUTICS, PSG COLLEGE OF PHARMACY Page 23 
 
 Figure 5: MECHANISM OF CODESTM 
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TABLETS: 
  Solid dosage forms are the most popular category of pharmaceutical formulations. 
They are in a sense ‗convenience‘ dosage forms and in comparison to the liquid formulations, 
their stability is of a high order. Within the solid dosage forms, unitary forms such as tablets, 
pills, capsules, cachets, wrapped powders rank high since they ensure accuracy in dosage. 
             A tablet is a pharmaceutical dosage form. Tablets may be defined as the solid unit 
dosage form of medicament or medicaments with or without suitable excipients and prepared 
either by molding or by compression. It comprises a mixture of active substances and excipients, 
usually in powder form, pressed or compacted from a powder into a solid dose. The excipients 
can include diluents, binders or granulating agents, glidants and lubricants to ensure effective 
tableting, disintegrants to promote tablet break-up in the digestive tract, sweeteners or flavours to 
enhance taste and pigments to make the tablets visually attractive or aid in visual identification 
of an unknown tablet. A polymer coating is often applied to make the tablet smoother and easier 
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to swallow, to control the release rate of the active ingredient, to make it more resistant to the 
environment (extending its shelf life) or to enhance the tablet‘s appearance. (Lieberman et al) 
          The compressed tablet is the most popular dosage form. About two-thirds of all 
prescriptions are dispensed as solid dosage forms, and half of these are compressed tablets. A 
tablet can be formulated to deliver an accurate dosage to a specific site; it is usually taken orally, 
but can be administered sublingually, buccally, rectally or intravaginally. The tablet is just one of 
the many forms that an oral drug can take such as syrups, elixirs, suspensions and emulsions. 
Tablet properties: 
 A tablet should have elegant product identity while free of defects like chips, 
cracks, discoloration, and contamination. 
 Should have sufficient strength to withstand mechanical shock during its 
production packaging, shipping and dispensing. 
 Should have the chemical and physical stability to maintain its physical attributes 
over time. 
 Must have a chemical stability over time so as not to follow alteration to the 
medicinal agents. 
 The tablet must be able to release the medicinal agents in a predictable and 
reproducible manner. 
Advantages: 
 Greatest dose precision and the least content variability. 
 Cost is lowest of all oral dosage form. 
 Lighter and compact. 
 Easiest and cheapest into package and strip. 
 Easy to swallowing with least tendency for hang-up. 
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Disadvantages: 
 Difficult to swallow in case of children and unconscious patients. 
 Drugs with poor wetting, slow dissolution properties, may be difficult to 
formulate or manufacture as a tablet that will still provide adequate or full drug 
bioavailability. 
 Some drugs resist compression into dense compacts, owing to amorphous nature, 
low density character. 
 Bitter testing drugs, drugs with an objectionable odor or drugs that are sensitive to 
oxygen may require encapsulation or coating. In such cases, capsule may offer the 
best and lowest cost. 
Tablet manufacturing: 
 The manufacture of granulations for tablet compression may follow one or a 
combination of three established methods. 
1. Direct compression method 
2. Dry or compression granulation method 
3. Wet granulation method 
Direct compression method: 
 Direct compression is a popular choice because it provides the shortest, most 
effective and least complex way to produce tablets. The manufacturer can blend an API with the 
excipient and the lubricant, followed by compression, which makes the product easy to process. 
No additional processing steps are required. 
Wet granulation method: 
   Granules are formed by the addition of a granulation liquid onto a powder bed 
which is under the influence of an impeller. The agitation resulting in the system along with the 
wetting of the components within the formulation results in the aggregation of the primary 
powder particles to produce wet granules. The granulation liquid contains a solvent which must 
be volatile. So that it can be removed by drying, water, ethanol, isopropanol are used. The liquid 
solution can be either aqueous based or solvent based. 
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   Figure 6: METHODS OF COMPRESSION 
 
Dry granulation method: 
  It is used to form granules without using a liquid solution because the product 
granulated may be sensitive to moisture and heat. Forming granules without moisture requires 
compacting and densifying the powders. In this process the primary powder particles are 
aggregated under the high pressure. When a tablet press is used for dry granulation, the powders 
may not possess enough natural flow to feed the product uniformly into die cavity. 
DELAYED RELEASE DOSAGE FORMS: 
 A delayed release dosage form is designed to release the drug at a time other than 
promptly after administration. Dosage forms can be designed to modify the release of the drug 
over a given time or after the dosage form reaches the required location. Delayed release oral 
dosage forms can control where the drug is released, e.g, when the dosage form reaches the small 
intestine (enteric coated dosage forms) or the colon (colon-specific dosage forms). Delayed 
release systems release a bolus of the drug after a predetermined time in a predetermined 
location, i.e. they do not release the drug immediately after ingestion, for example enteric coated 
tablets, pulsatile-release capsules. 
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 The coatings that are used today to produce enteric effects are primarily mixed 
acid functionality and acid ester functionality synthetic or modified natural polymers. Cellulose 
acetate phthalate has the longest history of use as an enteric coating. More recently, polyvinyl 
acetate phthalate and hydroxyl propyl methyl cellulose phthalate have come into use. All three 
polymers have the common feature of containing the di carboxylic acid, phthalic acid, in 
partially esterifies form. These polymers, being acid esters, are insoluble in gastric media that 
have a pH of up to about 4; they are intended to hydrate and begin dissolving as the tablets leave 
the stomach, enter the duodenum (pH of 4 to 6), and move further along the small intestine, 
where the pH increases to a range of 7 to 8. The primary mechanism by which these polymers 
lose their film integrity, thereby admitting intestinal fluid and releasing drug, is ionization of the 
residual carboxyl groups on the chain and subsequent hydration. The presence of esterases in the 
intestinal fluid that break down ester linkages of the polymer chains may also play some role, as 
may surface activity effects of bile salts and other components in bile that enter the upper small 
intestine via the bile duct. 
  Delayed release dosage forms are designed to provide spatial placement or temporal 
targeted delivery of a drug to the distal human gut. Spatial placement relates to targeting a drug 
to a specific organ or tissue, while temporal delivery refers to desired rate of drug release to 
target tissue over a specified period of time. The primary aim of using delayed release products 
is to protect the drug from gastric fluids, to reduce gastric distress caused by drugs particularly 
irritating to the stomach or to facilitate gastrointestinal transit for drugs that are better absorbed 
from intestine. Delayed release products are typically enteric-coated or targeted to the colon. 
EVALUATION OF TABLETS: 
PRE COMPRESSION PARAMETERS: 
Angle of repose: 
 The manner in which stresses are transmitted through a bead and the beads 
response to applied stress are reflected in the various angles of friction and response. The most 
commonly used of this in angle of repose, which may be determined experimentally by number 
of methods. The method used to find the angle of repose is to pour the powder a conical on a 
level, flat surface and measure the included angle with the horizontal.    
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                                       θ = Tan -1 (h/r)  
Where, θ = Angle of repose, h = Height of the powder cone, r = Radius of the powder cone. 
Bulk density: 
 Bulk density of a compound various substantially with the method of 
crystallization, milling or formulation. Bulk density is determined by pouring pre sieved granules 
into a graduated cylinder via a large funnel and measure the volume and weight.  (Pavani G et al) 
 Bulk density = weight of granules ÷ Bulk volume of granules  
Tapped density:  
 Tapped density is determined by placing a graduated cylinder containing a known 
mass of granules and mechanical tapper apparatus, which is operated for a fixed number of taps 
until the powder bed volume has reached a minimum volume, using the weight of the drug in the 
cylinder and this minimum volume, the tapped density may be computed.       
   Tapped density = weight of granules÷ Tapped volume of granules  
Carr's index:  
 Carr's index is measured using the values of bulk density and tapped density. The 
following equation is used to find the Carr's index 
                  CI   =    (TD-BD) x l ÷Tapped density  
Where TD = Tapped density 
BD = Bulk density   
Hausner's Ratio: 
  It indicates the flow properties of the powder and ratio of Tapped density to the 
Bulk density of the powder or granules.  
 Hausner's Ratio = Tapped density ÷ Bulk density 
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POST COMPRESSION PARAMETERS: 
Physical appearance: 
 The physical appearance of the compressed tablets involves the measurement of 
a number of attributes like tablet shape, smoothness, chipping, cracks, surface texture, color, 
embossing.  
Thickness:  
  Thickness was determined for 20 pre weighed tablets of each batch using a 
digital vernier scale and the average thickness was determined in mm. The tablets thickness 
should be controlled within a ±5% variation of standard.  
Weight variation:  
  20 tablets were selected randomly from a batch and were weighed individually 
and then average weight was calculated. The tablets meet the USP specifications if not more than 
2 tablets are outside the percentage limit and if no tablet differs by more than 2 times the 
percentage limit.  
Hardness test:  
  The crushing load which is the force required to break the tablet in the radial 
direction was measured using hardness tester. The hardness of 10 tablets was noted and the 
average hardness was calculated. 
Friability test:  
  In friability testing the tablets are subjected to abrasion and shock. It gives an 
indication of the tablets ability to resist chipping and abrasion during transportation and shipping. 
Tablets initial weight was noted. The tablets were rotated in Roche Friabilator for 100 
revolutions at 25rpm. The tablets were dedusted and reweighed. The %friability should be not 
more than l% w/w of the tablets being tested. The % friability is expressed as the loss of weight 
and is calculated  
  % Friability = (Wo – Wf) / Wo x 100 
 Wo - initial weight of tablets 
 Wf -final weight of tablets 
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Disintegration time: 
    It is the time taken by the tablet to breakup into smaller particles. The 
disintegration test is carried out in an apparatus containing a basket rack assembly with six glass 
tubes of 7.75 cm in length and 2.15mm in diameter, the bottom of which consists of a 10 mesh 
sive. The basket is raised and lowered 28 - 32 times per minute in a medium of 900ml which is 
maintained at 37˚C. Six tablets were placed in each of the tubes and the time required per 
complete passage of tablet through the 10 mesh was considered as the disintegration time of the 
tablet. 
Dissolution studies: 
 Dissolution is process by which a solid state enters a solution. In pharmaceutical 
industry it may be defined as the amount of drug substance that goes into solution per unit time 
under standardized conditions of liquid (or) solid interface, temperature and solvent composition. 
Dissolution is considered as one of the most important QC test performed on pharmaceutical 
dosage form and is now developing into a tool for predicting bioavailability 
            A) Apparatus1 (Basket Type): A single tablet is placed in a Wire mesh basket attached to 
the bottom of the shaft connected to a variable speed motor, the basket is immersed in a 
dissolution medium contained in a 1000 ml flask. The flask is cylindrical with hemispherical 
bottom and maintained at 37oC ± 0.5oC by a constant temperature bath. The motor is adjusted to 
turn at the specified speed and sample of the fluid is withdrawn at intervals‘ to determine the 
amount of drug in solution. 
            B) Apparatus2 (paddle type): It is same as apparatus 1 except basket is replaced by 
paddle. The dosage form is allowed to sink to the bottom of the flask before stirring. For 
dissolution test USP specifies the dissolution test medium and volume, type of apparatus to be 
used, RPM of the shaft, the time limit of the test, and assay procedure. The test tolerance is 
expressed as a % of the labeled amount of drug dissolved in the limit. 
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LITERATURE REVIEW 
Amir Dustgani et al., (2008) have studied about chitosan nanoparticles were used to describe 
the synthesis and characterization of novel biodegradable nanoparticles for encapsulation of 
dexamethasone sodium phosphate. Ionic gelation method was used for preparation of 
nanoparticles. These drug containing nanoparticles were prepared with different amounts of 
drug. The method based on the interaction between the negative groups of sodium tri 
polyphosphate (TPP) and the positively charged amino groups of chitosan. Dexamethasone 
sodium phosphate loaded nanoparticles were obtained according to the same procedure. The 
mean size and size distribution of nanoparticles were measured by dynamic laser light scattering. 
S. Latha et al., (2012) have formulate the capecitabine loaded nanoparticles of chitosan (CS) 
cross linked with tri polyphosphate (TPP) for anti-cancer therapy, in order to enhance the 
bioavailability and reduce dose frequency. Then the nanoparticle solution was prepared by 
dissolving chitosan (CS) in 1% (w/v) acetic acid solution under magnetic stirring under room 
temperature. The chitosan solution was diluted with deionized water to produce different 
concentration. The nanoparticle average size was found to be in the range of 120-250 nm and it 
is spherical in shape with high zeta potentials. In vitro release studies in phosphate buffer pH 7.4 
showed an initial burst effect and followed by a slow drug release. Then the drug release 
followed zero order kinetics. This study concluded that the encapsulation of capecitabine into 
chitosan can significantly improve the anticancer activity. 
Varshosaz J et al., (2011) have discussed about the development of budenoside pellets based on 
a novel colon drug delivery system. Budenoside is the drug of choice for treatment of active 
inflammatory bowel disease (IBD). Pellets were prepared by extrusion (or) spheronization and 
coated with an acid soluble polymer, HPMC and an enteric coated polymer sequentially. In vitro 
drug release of coated pellets was studied using USP dissolution apparatus type 2 in buffers of 
pH 1.2,7.4,6.8.The morphology of optimized formulations of coated pellets was characterized 
using scamming electron microscopy. This study suggests that pellets based on codestm 
technology could be useful for colonic delivery. 
Kishore M et al., (2015) explained that a novel colon specific drug delivery system of an Anti 
hypertensive drug is atenolol, for treatment of chronic cardiac diseases like Heart failure, sudden 
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increases in blood pressure was developed. Mini tablets of Atenolol were prepared by wet 
granulation method using matrix forming natural polymers. The further effect of enteric coat on 
the mini tablets for colon specific drug release was investigated. The Atenolol optimized matrix 
formulation shows drug release around 32.37±0.33% in 2 hrs. So it was further enteric coated 
with eudragit S100 in cumulative ratio and formulated the formulations. Apart from the 
formulation showed optimum drug release after 24 hrs. All formulations were subjected to 
Hardness test, Friability test, determination of uniform diameter and thickness, drug content for 
optimization and further evaluation. In vitro dissolution studies revealed that the drug release in 
upper part of GIT from matrix tablets of Atenolol can be prevented by enteric coating with pH 
sensitive polymer (EudragitS100), which releases the drug specifically in colonic region to 
achieve target delivery. For drug release three dissolution media with pH 1.2, 7.4 and 6.8 were 
used sequentially. These three media represents the stomach, proximal part of the small intestine 
and terminal ileum respectively. 
Claudia S. LEOPOLD et al., (1998) have described about the study was to investigate an acid-
soluble polymer as coating material for multiple units with regard to its ability to allow drug 
release only under the acidic conditions of the inflamed colon. Mini tablets containing 20% 
(w/w) of the model drug dexamethasone with or without the muco adhesive swelling agent 
carbomer 934 (neutralized) were coated in a small coating pan with different amounts of an 
organic solution of eudragit E. Drug release from the eudragit E-coated cores at pH 2.0- 5.0 
starts after 10-50min due to the rapid dissolution of the eudragit E film. At pH 6.8 lag times of 
drug release depend on the composition of the cores and the thickness of the coating film. In the 
case of the carbomer containing cores drug release is induced by disruption of the coating film 
due to swelling of the cores and lag times (up to 20 h) increase over proportionately with 
increasing coating thickness. With no swelling agent in the cores drug release at pH 6.8 is 
delayed due to the low erosion (or) dissolution rate of eudragit E. Lag times of drug release (up 
to 33 h) increase in a linear manner with increasing coating thickness. Thus, eudragit E, 
protected against dissolution in the stomach by an enteric coating, is a suitable coating polymer 
for drug release in acidic regions such as the inflamed colon. 
Sampath et al., (2014) stated that long-term uses of non-selective NSAIDs can lead to 
gastrointestinal toxicity from sustained inhibition COX-1. But one can overcome such problem 
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by formulating them as colon specific delivery. The present study was carried out to develop oral 
colon targeted drug delivery system for nimesulide utilizing recently designed and patented 
system called CODESTM, which consisted of a lactulose containing core over coated with both 
eudragit E and eudragit L designed to rapidly disintegrate in the colon, in order to give a new life 
for an existing banned drug. CODESTM tablets were prepared by tableting the granulation of 
nimesulide and lactulose, followed with film coating. The prepared tablets were evaluated on the 
basis of various pharmacopoeial characteristics. The onset of nimesulide release was found to 
dependent on the coating level of eudragit E, and at eudragit E, the onset of in vitro drug release 
was found to be optimum. It is concluded that nimesulide can be targeted to hindgut by Novel 
approach of CODESTM in a simple and economic way. From the obtained results, it can be 
concluded that drug release and absorption of nimesulide can be targeted on the colon by 
CODES system. Evaluation parameters like hardness and friability indicated that the tablets so 
prepared were mechanically stable and complied with necessary pharmacopoeial specifications. 
I.R. spectra revealed that, the drug and polymers are authentic and match with the reference 
standard available and there is no interaction between polymers and drug.  
Sukhbir Kaur et al., (2014) have investigated about matrix tablets of indomethacin were 
prepared by wet granulation method. Guar gum and Pectin as a carrier, 10% starch paste, di 
calcium phosphate is used as diluents and the mixture of talc and magnesium stearate at 2:1 ratio 
were used. All the prepared formulations were evaluated for hardness, drug content uniformity 
and were subjected to in vitro drug release studies. In vitro drug release study was conducted at 
37 ºC and 100 rpm for 2 h in 900 ml buffer of pH 1.2. The dissolution medium were replaced 
with 900 ml of pH 7.4 phosphate buffers and tested for drug release up to 3 h. Drug release study 
was continued for 24 hours in 6.8 pH phosphate buffer. Colorectal cancer, is a cancer from 
uncontrolled cell growth in the colon or rectum (parts of the large intestine), or in the appendix. 
It is forth most commonly diagnosed cancer in the world. Symptoms of the disease include rectal 
bleeding and anemia which are sometimes associated with weight loss, changes in bowel habits, 
fever, loss of appetite, and nausea or vomiting. So in order to treat this disease colon targeted 
delivery of indomethacin is designed using natural polysaccharides i.e. pectin and guar gum for 
site specific delivery. These carriers were degraded by colonic bacteria hence delivering the drug 
colon region. 
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Jennifer I. Hare et al., (2013) have investigated the use liposomal irinotecan (Irinophore C
TM
) 
plus or minus 5-fluorouracil (5-FU) for the treatment of colorectal cancer. The effect of 
irinotecan (IRI) and/or 5-FU exposure times on cytotoxicity was assessed in vitro against HT-29 
or LS174T human colon carcinoma cells. The pharmacokinetics and bio distribution of 
Irinophore C
TM
 (IrC
TM
) and 5-FU, administered alone or in combination, were compared in vivo. 
A subcutaneous model of HT-29 human colorectal cancer in Rag2-M mice was utilized to assess 
the efficacy of IrC
TM
 alone, and in combination with 5-FU. This strategy has been shown to be 
important for producing synergistic anti-cancer effects with floxuridine and other drug 
combinations. Finally, it may be prudent to explore the use of leucovorin to potentiate the 
efficacy of 5-FU in the HT-29 model. 
Subal  Chandra Basak et al., (2008) studied about a metformin hydrochloride (metformin HCl) 
was formulated as a hydrophobic matrix sustained release tablet employing wax materials and 
the sustained release behavior of the fabricated tablet was investigated. The tablets were prepared 
by wet granulation technique. The formulation was optimized on the basis of acceptable tablet 
properties and in vitro drug release. Then the resulting formulation produced monolithic tablets 
with optimum hardness, uniform thickness, consistent weight uniformity and low friability. 
Statistically significant differences were found among the drug release profile from different 
bees wax combination matrices. The results of dissolution studies exhibited drug release pattern 
very close to theoretical release profile. Applying kinetic equation models, the mechanism of 
release of the drug from the three formulations was found to be followed Higuchi model, as the 
plots showed high linearity, with correlation coefficient (R
2
) value of 0.98 or more. Tablet 
matrices containing cetyl alcohol gave better release of the drug than other materials studied. 
However, the rate of release varied with amount of cetyl alcohol in the matrix. The „n‟ value lies 
below 0.5 demonstrating that the mechanism controlling the drug release was the quasi Fickian. 
Approach of the study was to make an evaluation of wax materials as sustained release matrix 
for water soluble drug, metformin HCl and to assess the kinetics of drug release mechanism. 
Bees wax and cetyl alcohol can be used for sustained release of metformin HCl. The study 
reveals that, the release of water soluble drug, metformin HCl exhibited diffusion dominated 
mechanism. The wax and cetyl alcohol ratio plays an important role in overall release of the 
drug. The hydrophobic wax matrix tablet is a promising approach to achieve appropriate 
sustained release dosage. 
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Ghassan Zuhair Abdullah et al., (2013) have explained about micro emulsions and nano 
emulsions are well known candidates to deliver drugs locally. However, the poor rheological 
properties are marginally affecting their acceptance pharmaceutically. This work aimed to 
modify the poor flow properties of a nano scaled emulsion comprising palm olein esters as the 
oil phase and ibuprofen as the active ingredient for topical delivery. Three carbopol resins: 934, 
940 and ultrez 10, were utilized in various concentrations to achieve these goals. Moreover, 
phosphate buffer and tri ethanolamine solutions pH 7.4 were used as neutralizing agents to assess 
their effects on the gel-forming and swelling properties of carbopol 940. The addition of these 
polymers caused the produced nano scaled emulsion to show a dramatic droplets enlargement of 
the dispersed globules, increased intrinsic viscosity, consistent zeta potential and transparent-to-
opaque change in appearance. Carbopol 940 and tri ethanolamine appeared to be superior in 
achieving the proposed tasks compared to other materials. The higher the pH of tri ethanolamine 
solution, the stronger the flow modifying properties of carbopol 940. Transmission electron 
microscopy confirmed the formation of a well arranged gel network of carbopol 940, which was 
the major cause for all realized changes. This study resulted in in vitro and in vivo 
pharmacodynamics properties that are comparably higher than the reference chosen for this 
study.  
Sovan Lal Pal et al., (2011) describes the development of novel drug delivery systems using 
nanoparticles. Nanoparticles can offer significant advantages over the conventional drug delivery 
in terms of high stability, high specificity, high drug carrying capacity, ability for controlled 
release, possibility to use in different route of administration and the capability to deliver both 
hydrophilic and hydrophobic drug molecules. This review focuses on classification, methods of 
preparation, characterization, application, advantages of nanoparticles and health perspectives. 
Pranav Palshikar et al., (2013) this study was to develop an enteric coated tablet of sodium 
valproate using cellulose acetate phthalate as enteric coating material. Core tablet were prepared 
by non-aqueous granulation method and seal coated with PVP K-30 which act as moisture 
barrier. This seal coated tablet was further coated with cellulose acetate phthalate to dissolve in 
the intestinal fluid. The in vitro release result showed that enteric coated were capable of 
restricting release in the acidic media. The enteric coating was applied with the consideration of 
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transit time of food or dosage form from stomach to jejunum of small intestine and from percent 
release verses time plot was plotted. 
Sateesh Kumar Vemula et al., (2015) the aim of the study is focused on developing 
flurbiprofen colon-specific tablets based on timed release and pH-sensitivity. The effect of 
eudragit coating on the drug release from hydroxyl propyl methylcellulose matrix to achieve the 
colon-specific release. Tablets were prepared by wet granulation method and coated with 
eudragit S100 using dip coating method. Then the tablets were evaluated for different physical 
parameters, compatibility studies, in vitro dissolution and in vivo x-ray imaging studies. 
Flurbiprofen colon-specific tablets have been characterized for weight variation, hardness, 
friability and drug content. Compatibility studies revealed that there was no interaction between 
drug and the polymers. In support of the dissolution studies, x-ray imaging studies revealed that 
tablets reached the colon without disintegrating in the upper gastro intestinal tract. It concluded 
that the developed flurbiprofen enteric coated matrix tablets are suitable for colonic delivery. 
Hina Kouser Shaikh et al., (2015) this study reviewed the application of mathematical models 
for study of release phenomenon of drug from dosage forms. Mathematically, it is easy to 
identify the designing of a particular pharmaceutical system and it can be used to predict the 
effect of device design parameters on the release kinetic of the formulation. It is easier to obtain 
the quantitative analysis of data for dissolution release rate by using these models. The choice of 
selection of best model depends on the desired or required predictive ability and accuracy of the 
model. This review gives the idea about the current state of mathematical modeling of drug 
delivery including empirical (or) semi empirical and mechanistic release models. The drug 
release shows the relationship between drug dissolution and geometry on drug release patterns 
mathematically. The fact that drug delivery system with multi layered tablet has shown 
promising results in drug delivery technology and ease of manufacturing is an advantage to the 
pharmaceutical industries. 
V R Sinha et al., (2006) have described to formulate fast release enteric-coated tablets for drug 
delivery to the colon. Two different approaches were used for the preparation of these tablets. 
The ﬁrst included making use of super disintegrant (SD) in the tablet. The amount of super 
disintegrant in the tablet and the coat weight were varied to formulate a suitable time-controlled 
release system that would provide colon-speciﬁc drug delivery. The second approach consisted 
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of development of osmogen-based tablets for drug delivery into the tracts of the colon. Two 
different osmogens, sodium chloride and potassium chloride, were used. These also were coated 
at different coat levels. Celecoxib was used as a model drug. Invitro drug release studies showed 
that super disintegrants were more effective in showing burst effect in the tablets and therefore 
showed a rapid drug release as compared with osmogens, which would show a sustained drug 
release all through the colon. Osmotic tablets were formulated making use of a high 
concentration of osmogen sodium chloride and potassium chloride were further enteric coated.  
Namrata Patel et al., (2015) have stated about capecitabine beads were formulated by an 
ionotropic gelation method. Analysis of response surface plots allowed identification of an 
optimized formulation with high drug entrapment and controlled release. Insignificant 
differences in observed and predicted values for responses validated the optimization method. 
Optimized beads possessed an average diameter and good flow properties. Their production as 
spherical beads having a smooth surface was confirmed by scanning electron microscopy. 
Fourier transform infrared spectroscopy revealed the compatibility of drug with added excipients 
while differential scanning calorimetry study confirmed the complete drug entrapment in 
polymer matrix. Higher swelling of beads in phosphate buffer pH 7.4 was obtained in 
comparison to pH 6.8. Invitro dissolution studies of beads loaded into enteric coated capsules 
revealed negligible release in simulated gastric as well as intestinal fluid, followed by 49.23% 
release in simulated colonic fluid, in 4 hours. In conclusion, the formulated beads showed colon 
specific controlled release properties and thus could prove to be effective for colon cancer 
treatment. 
M. P. Bhandarwad et al., (2015) explained about pH dependent system and time dependent 
system, microbial degradation at the required site is effective for treatment. Solvent less 
compression coating is one of the strategies for delivering drugs to the colon based on microbial 
degradation. The aim of the research was to develop a polymer based compression coated tablet 
of 5-Fluorouracil and to identify the most suitable polymer either alone or in combinations for 
colonic delivery. Core  tablets  of  5-Fluorouracil  were  compression  coated  with various  
proportions  of Guar  gum,  xanthum  gum  and  Chitosan. Drug  release  studies were  performed  
in  simulated  gastric  fluid (SIG)  for  2  hours  followed  by simulated intestinal fluid (SIF)  up  
to  24  hours, demonstrating  that  the  rate  of  drug  release  is dependent  upon  the  nature  and 
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concentration  of  polymer and the pH of environment. The coat containing guar gum or xanthum 
gum alone showed 30-40% drug release in 8 hours in SIF while guar gum with xanthum gum 
showed 30-35% drug release in 8 hours in SIF. The coat containing all three polymers showed 
45 to 50% drug release in SIF. Further, in  vitro dissolution studies  performed  in  the  
dissolution  media  with 2%  rat  ceacal  content  showed significantly increased drug  release 
because of microbial polysaccharidase enzyme.   
Nandgude Tanagi Dilip et al., (2016) have briefly explained about to develop a multi 
particulate system containing chitosan microspheres for colon-specific drug delivery of 
capecitabine for the treatment of colorectal cancer. This study was based on the microbial 
degradability of chitosan microspheres. The microspheres were prepared with chitosan by 
emulsion cross linking method. The effect of concentration of chitosan and drug: Polymer ratio 
was studied on particle size, % entrapment efficiency, and % drug release. The prepared 
microspheres also analyzed for percentage yield, flow properties, and surface morphology. The 
results of analysis of variance test for responses measured indicated that the test is statistically 
significant. In vitro drug release studies were performed in a pH progression medium mimicking 
the conditions of the gastro intestinal tract showed a fast drug release initially demanded micro 
encapsulation. 
Laila Fatima Ali Asghar et al., (2009) the primary objective of the study was to develop a pH 
and transit time controlled sigmoidal release polymeric matrix for colon-specific delivery of 
indomethacin. Tablet matrices were prepared using a combination of hydrophilic polymers 
(polycarbophil or carbopol) having pH sensitive swelling properties with hydrophobic polymer 
ethyl cellulose. The prepared matrices were characterized for physical properties and in vitro 
release kinetics. The presence of ethyl cellulose in a hydrophilic polymer matrix resulted in a 
sigmoidal in vitro drug release pattern with negligible to very low drug release in the initial 
phase (0–6 h) followed by controlled release for 14–16 h. The retardation in initial release can be 
attributed to the presence of ethyl cellulose that reduced swelling of hydrophilic polymer while 
in the later portion, polymer relaxation at alkaline pH due to the ionization of acrylic acid units 
on carbopol and polycarbophil resulted in enhanced drug release. Thus, a sigmoidal release 
pattern was obtained that could be ideal for colonic delivery of indomethacin in the potential 
treatment of colon cancer. 
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Jitendra Jagtap et al., (2013) have discussed about the delivery of drugs to the colon through 
oral route is valuable in treating diseases of the colon with the expectation to protect the drug 
during the transit time in the gastrointestinal tract and to allow its release only in the colon. This 
study was to develop colon targeted drug delivery system for satranidazole that is used in the 
treatment of amoebiasis. Matrix tablets containing a combination of guar gum and hydroxyl 
propyl methyl cellulose (HPMC) K4M in different ratios were prepared by wet granulation 
technique followed by enteric coating with eudragit S100. Citric acid was also added, which 
might further facilitate drug dissolution and absorption. All formulations were evaluated for 
hardness, swelling, drug content and in‑vitro drug release studies. The results of the studies 
showed that colon targeted matrix tablet of satranidazole containing guar gum and HPMC K4M 
in the ratio proportion of 3:1 does not released drug in 0.1N HCl (pH 1.2) and small intestine 
(phosphate buffer, pH 7.4). When the dissolution study was continued in colonic fluids 
(phosphate buffer, pH 6.8. It was expected that guar gum could be degraded by colonic micro 
flora containing anaerobic microorganism and the release may be controlled by HPMC K4M and 
citric acid. Studies demonstrated that orally administered satranidazole matrix tablets can be used 
effectively for the delivery of the drug to the colon. 
Sahdeo Prasad et al., (2012) stated about the development of chemo resistance, poor prognosis, 
and metastasis often renders the current treatments for colorectal cancer (CRC) ineffective. 
Whether ursolic acid (UA), a component of numerous medicinal plants, either alone or in 
combination with capecitabine, can inhibit the growth and metastasis of human CRC was 
investigated.  The effect of UA on proliferation of colorectal cancer cell lines was examined by 
mitochondrial dye-uptake assay, apoptosis by esterase staining, DNA binding assay and protein 
expression by western blot. This study resulted that UA inhibited the proliferation of different 
colon cancer cell lines.  Overall our results demonstrate that UA can inhibit the growth and 
metastasis of CRC and further enhance the therapeutic effects of capecitabine through 
suppression of multiple biomarkers linked to inflammation, proliferation, invasion, angiogenesis, 
and metastasis. 
Sylwia Flis et al., (2009) have explained about COX inhibitors appear to be promising agents in 
combination with cytostatics in the treatment of colorectal carcinoma (CRC). The aim of this 
study was to compare growth inhibitory effects of cytostatics (5-fluorouracil, 5-FU; oxaliplatin) 
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and COX inhibitor sulindac sulfide (an active metabolite of sulindac), given alone or in 
combination, on several CRC cell lines. A series of human CRC cell lines were incubated with 
various combinations of the test drugs used in concentrations from 3 to 200 μm. The cell survival 
was assessed by MTT assay. Cell cycle progression and apoptosis were measured using flow 
cytometric methods. In addition, growth inhibitory effects of studied agents on CRC cell lines 
were compared with a normal cell line. Sulindac sulfide synergistically potentiated the inhibitory 
effects of 5-FU and oxaliplatin on CRC survival, parallel to the induction of apoptosis. A dose 
reduction effect for synergistic activity of sulindac sulfide with studied cytostatics suggested that 
the inhibitory effect of cytostatics on CRC survival may be obtained at low doses. It was 
apparent that combination of 5-FU or oxaliplatin with sulindac sulfide results in a powerful 
inhibition of growth of colorectal carcinoma cells in vitro, which may be more specific for 
cancer than normal cells. The effect of combinations of sulindac sulfide with 5-FU or oxaliplatin 
on survival of human CRC cells of various cell lines was studied in vitro. 
Prasanth V.V et al., (2012) stated about colon specific drug delivery system in order to develop 
drug delivery systems that are able to release drugs specifically in the colon in a predictable and 
reproducible manner. The colon is a site where both local and systemic delivery of drugs can 
take place. To achieve successful colon targeted drug delivery, a drug need to be protected from 
degradation, release and absorption in the upper portion of the gastric intestinal tract (GIT) and 
then to be ensured abrupt or controlled release in the proximal colon. This review is aimed at 
understanding recent approaches for dosage forms which is targeting to colon through pH 
sensitive system, microbially triggered system i.e., pro drugs and polysaccharide based system, 
timed release system, osmotically controlled drug system, pressure dependent release system. It 
concluded that the colonic region of the GIT has become an increasingly important site for drug 
delivery and absorption. Drug targeting to the diseased colon is advantageous in reducing the 
systemic side effects, lowering dose of a drug, supply of the drug only when it is required and 
maintenance of the drug in its intact form as close as possible to the target site. All the 
approaches of colon drug delivery provide means for treatment of local diseases associated with 
the colon or for systemic absorption of poorly absorbable drugs.  
A Maria John Newton et al., (2012) the study was designed to evaluate the in vitro dissolution 
characteristics of pH-sensitive polymer (HPMC E 15 LV) coated tablets in various simulated 
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fluids. The mesalamine tablets were fabricated by mixing the drug with micro crystalline 
cellulose and other ingredients. The fabricated mesalamine tablets were coated with eudragit 
L100 polymer and HPMC E 15 LV. The fluctuation in colonic pH conditions during 
inflammatory bowel disease and the nature of less fluid content in the colon may limit the 
expected drug release in the colon. The different batches of mesalamine tablets were coated with 
increasing concentration of eudragit L100 and HPMC E 15 LV. The different buffer conditions 
were chosen to mimic the pH changes in the terminal part of the ileum as well as in the colon. 
The drug release profile was analyzed for colon-targeting performance in vitro. The kinetics of 
the drug release also evaluated the release pattern that was best fitted with Higuchian release. 
The results of the mechanism of release revealed that drug release was found to be a complex 
one with diffusion, erosion and swelling. Mesalamine delayed release tablets was prepared 
successfully by coating with eudragit L100 and HPMC E15 LV as polymers to retard the drug 
release and achieve a required dissolution profile. The drug release studies revealed that the pH-
sensitive eudragit L100 can retard the drug release from the tablet until the tablet reaches the 
colon. The coated tablets released maximum amount of drug in pH conditions of the colon and 
the terminal part of the intestine. Drug release kinetics indicated that drug release was best fitted 
to the Hixson–Crowell release kinetics. The “n” value of Korsmeyer–Peppas confirmed that the 
complex mechanism of swelling diffusion and erosion was involved in the drug release. This 
study suggests that this simple coating technique may be considered as an alternate method for 
delivery of drug to the colon to achieve better targeting and pharmacological effects in the 
treatment of IBD. 
G. Pavani et al., (2013) the objective of the present investigation was to formulate and devaluate 
sustained release of capecitabine tablets. capecitabine sustained release tablets were developed 
different polymers HPMC K 100, carbopol 974 and Xanthan Gum with different ratios. 
Sustained release tablets of capecitabine were prepared by wet granulation technique. The 
prepared granules evaluated in terms of their pre compression studies like tapped density, bulk 
density, angle of repose, carr‟s Index and hausner‟s ratio. The tablets were evaluated by post 
compression studies like hardness, thickness, friability and in vitro studies. From the dissolution 
study the R
2
 value of Higuchi model is very near to 1 than the R
2 
values of the other kinetic 
models. 
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Tarak J Mehta et al., (2011) the aim of present study was to develop colon-specific drug 
delivery systems based on polysaccharide chitosan, were evaluated using in-vitro method. 
Metronidazole is choice of drug for intestinal amoebiasis. These drugs are to be delivered to the 
colon for their effective action against E. histolytica wherein the trophozoites reside in the lumen 
of the caecum and large intestine and adhere to the colonic mucus and epithelial layers. But the 
pharmacokinetic profile of metronidazole indicates that the drug is completely and promptly 
absorbed after oral administration. The administration of this drug in conventional tablet dosage 
form provides minimal amount of metronidazole for local action in the colon, still resulting in 
the relief of amoebiasis, but with unwanted systemic effects. The Amount of chitosan and 
carbopol 934P showed significant effect on the release of metronidazole from the colon specific 
tablet formulation. Present study summarized that chitosan and carbopol can be used 
successfully to deliver the drug in to colon. 
Venkateswara Reddy et al., (2015) have discussed about the sustained release matrix 
formulation of meloxicam targeted to colon by using various polymers developed. Meloxicam is 
a selective cyclooxygenase-2 inhibitor with pH-dependent solubility. To achieve pH-independent 
drug release of meloxicam, pH modifying agents (buffering agents) were used. Colon targeted 
tablets were prepared in two steps. Initially core tablets were prepared and then the tablets were 
coated by using different pH dependent polymers. Ethyl cellulose, eudragit L100 and S100 were 
used as enteric coating polymers. The pre compression blend of all formulations was subjected to 
various flow property tests and all the formulations were passed the tests. The tablets were 
coated by using polymers and the coated tablets were subjected to various evaluation techniques. 
The prepared formulations which may be used for prolong drug release in colon for, thereby 
improving patient compliance and bioavailability. 
Teelavath Vijayakumari et al.,(2015) stated about to develop colon targeted matrix tablets of 
glipizide using various concentrations of selected polymers are hydroxy propyl methyl cellulose 
and  Guar gum. Tablets were prepared by direct compression method. The compatibility of drug, 
polymers and excipients were studied by FT-IR spectroscopy. Dissolution studies were 
performed for 12 hours in 1.2 pH, 7.4 pH, 6.8 pH respectively in phosphate buffer at the 
temperature of 37±0.5˚C at 100 rpm. The dissolution data so obtained was fitted to various 
mathematical kinetic models and the drug release followed mixed order and Higuchi‟s model. To 
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study release mechanism of the drug from matrices the data were fitted to Koresmeyer – peppas 
model. In vitro release profile of glipizide from all polymers which are used in study showed that 
drug increasing the concentration of polymers resulted in a reduction in the release rate of the 
drug.  
Anbarasan B et al., (2015) this present study was to investigate the synthesis of Fe3O4 
nanoparticles by chemical precipitation method. The Fe3O4 nanoparticles were coated with the 
polymers PLGA- PEG and loaded with the drug capecitabine for the targeting of colon cancer 
which will be distributed in the large intestine by applying, the external magnetic field. It gets 
localized in the area of colon cancer cells. After the applied external magnetic field, the iron 
oxides get heated to 37ºC - 40ºC and the tumour cell gets destroyed. They were very smart 
materials and mostly used for the applications in medicine like targeted drug delivery system, 
diagnostic cancer imaging and their therapeutic applications. Also the Entrapment Efficiency 
(%EE) of the drug was calculated. Further, the particle size can be found by particle size 
analyzer (PSA). The surface morphology of the formulations was analyzed by SEM analysis. 
Vijaya Muthumanikandar et al., (2011) explained about the obtained pure drug mesalamine 
were identified by the FT-IR studies and the particle size were determined. The drug polymer 
compatibility studies were determined by using FT-IR study and found out no interaction 
between the drug and polymers. Colon targeted drug delivery system of mesalamine tablets were 
prepared by using different formula by wet and dry granulation method, the successful batches 
were determined. All the prepared granules were evaluated for the flow properties by studied the 
angle of repose, compressibility index and hausner‟s ratio. The prepared granules were studied 
for the particle size determination by using Malvern particle size analyzer. The prepared tablets 
were evaluated the hardness, friability, weight variation and disintegration studies. The prepared 
tablets were coated and the optimized coating formula were analyzed. The enteric coated tablets 
were analyzed for the disintegration, dissolution and drug content 
Sanket D Gandhi et al., (2010) the objective of the present study is to develop colon targeted 
drug delivery system for ivermectin using guar gum as a carrier in the treatment of helminthiasis. 
Matrix tablets containing various proportions of guar gum were prepared by wet granulation 
technique using starch paste as a binder. The idea was that the enteric coating would prevent 
drug release and absorption in the upper gastro intestinal tract. All the formulations were 
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evaluated for hardness, drug content uniformity and were subjected to in vitro drug release 
studies. The amount of  ivermectin released from the matrix tablets at different time intervals 
was estimated by a UV Spectroscopy method. Colon targeted matrix tablet of ivermectin 
containing Guar gum released no ivermectin in the physiological environment of stomach (0.1N 
HCL) and small intestine (phosphate buffer 7.4pH). When the dissolution study was continued in 
simulated colonic fluids (Phosphate buffer 6.8 pH) the matrix tablets released. 
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AIM AND OBJECTIVE OF THE STUDY 
 
AIM: 
                To prepare and evaluate chitosan nanoparticles loaded capecitabine drug  
formulation used for colorectal cancer. 
 
OBJECTIVES: 
 To prepare capecitabine nanoparticles by ionic gelation method. 
 
 To study the particle size and morphology of prepared capecitabine nanoparticles. 
 
 To formulate prepared nanoparticles into tablets. 
 
 To evaluate the tablets. 
 
 To study the in-vitro release of prepared tablets. 
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PLAN OF WORK 
Phase: 1  
 Drug profile 
 Polymer profile 
 Excipient profile 
 Preformulation studies 
Phase: 2 
 Preparation of capecitabine nanoparticulate formulation by ionic gelation method. 
Phase: 3 
     Characterization of nanoparticulate formulation 
 Particle size determination 
 Zeta potential determination 
 Phase contrast microscopy of nanoparticles 
 Scanning electron microscopy 
 Drug content and entrapment of formulation 
Phase: 4 
 Evaluation of flow properties of freeze dried products. 
Phase: 5 
 Preparation of enteric coated tablets of capecitabine nanoformulation using CODESTM 
technology. 
Phase :6 
 Weight variation  
 Hardness test 
 Thickness test 
PLAN OF WORK 
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 Friability test 
 Invitro release study 
 Drug release kinetics 
Phase :7 
 Cell line studies. 
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DRUG PROFILE 
 
Drug name Capecitabine 
Synonym 5'-Deoxy-5-fluoro-N [(pentyloxy)carbonyl]-cytidine 
Common name           Xeloda 
Classification Antimetabolite 
IUPAC name   pentyl N-{1-[(2R, 3R, 4S, 5R)-3, 4-dihydroxy-5- 
methyloxolan-2- yl] -5- fluoro-2-oxo-1, 2-dihydropyrimidin-4-
yl} carbamate. 
CAS number            154361-50-9 
Weight   Average: 359.3501   
Mono isotopic: 359.149263656 
Chemical formula C15H22FN3O6      
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Structure 
 
Description Capecitabine is a pro drug that is enzymatically converted to 
fluorouracil (anti-metabolite) in the tumor, where it inhibits 
DNA synthesis and slows growth of tumor tissue. 
Capecitabine is an orally-administered chemotherapeutic agent 
used in the treatment of metastatic breast and colorectal 
cancers. This compound belongs to the class of organic 
compounds known as glycosylamines. These are compounds 
consisting of an amine with a beta-N-glycosidic bond to a 
carbohydrate, thus forming a cyclic hemiaminal ether bond.  
Indications For the treatment of patients with metastatic breast cancer 
resistant to both paclitaxel and an anthracycline-containing 
chemotherapy regimen. It can also be used in combination 
with docetaxel for the treatment of metastatic breast cancer in 
patients, who have failed to respond to, or recurred or relapsed 
during or following anthracycline-containing chemotherapy. 
Capecitabine is used alone as an adjuvant therapy following 
the complete resection of primary tumor in patients with stage 
III colon cancer when mono therapy with fluropyrimidine is 
preferred. The use or capecitabine in combination regimens for 
advanced gastric cancer is currently being investigated. 
Route of 
administration 
Oral 
Mechanism of action Capecitabine is a prodrug that is selectively tumor-activated to 
its cytotoxic moiety, fluorouracil, by thymidine phosphorylase, 
an enzyme found in higher concentrations in many tumors 
compared to normal tissues or plasma. Fluorouracil is further 
metabolized to two active metabolites, 5-fluoro-2'-
deoxyuridine 5'-monophosphate (FdUMP) and 5-fluorouridine 
triphosphate (FUTP), within normal and tumor cells. These 
metabolites cause cell injury by two different mechanisms. 
First, FdUMP and the folate cofactor, N5-10-methylene tetra 
hydrofolate, bind to thymidylate synthase (TS) to form a 
covalently bound ternary complex. This binding inhibits the 
formation of thymidylate from 2'-deaxyuridylate. Thymidylate 
is the necessary precursor of thymidine triphosphate, which is 
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essential for the synthesis of DNA, therefore a deficiency of 
this compound can inhibit cell division. Secondly, nuclear 
transcriptional enzymes can mistakenly incorporate FUTP in 
place of uridine triphosphate (UTP) during the synthesis of 
RNA.  
Absorption Readily absorbed through the GI tract (~70%). After oral 
administration, capecitabine is rapidly taken up from the gut 
and converted into its main metabolites 5-deoxy-5-fluoro 
cytidine (5- DFCR) and 5-deoxy-5-fluorouridine (5 - DFUR). 
Systemic levels of 5-FU are low. Concomitant food intake 
significantly reduces the systemic exposure to capecitabine. It 
is recommended to take the drug after a meal because this has 
also been done in the clinical trials. The time to reach the 
maximal plasma concentration after food ingestion is around 2 
hours. Oral pharmacokinetics are linear. The absolute 
bioavailability is estimated to be 40%–45%  
Protein binding Binding is mainly to albumin and is 54% for capecitabine and 
10%, 62%, and 10% for its metabolites 5 - DFCR, 5 - DFUR, 
and 5-FU, respectively. No relevant interactions at this level 
are to be expected. 
Metabolism After oral uptake, capecitabine is first metabolized to 5 - 
DFCR, which takes place mainly in the liver by carboxyl- 
esterase. The metabolite is converted to 5-DFUR by cytidine 
deaminase in liver and tumor tissue and converted to 5-FU 
intracellularly by thymidine phosphorylase, an enzyme that is 
often expressed in tumor tissue. Catalytic inactivation of 5-FU 
proceeds by dihydro pyrimidine dehydrogenase (DPD), which 
is poly morphically express. 
 
Elimination Capecitabine and its metabolites are predominantly                             
excreted in urine; 95.5% of administered capecitabine dose is 
recovered in urine. Fecal excretion is minimal (2.6%). About 
3% of the administered dose is excreted in urine as unchanged 
drug. 
Pharmacodynamics Capecitabine is a fluropyrimidine carbamate with anti-
neoplastic activity indicated for the treatment of metastatic 
breast cancer and colon cancer. It is an orally administered 
systemic pro drug that has little pharmacologic activity until it 
is converted to fluorouracil by enzymes that are expressed in 
higher concentrations in many tumors. Fluorouracil it then 
metabolized both normal and tumor cells to 5-fluoro-2′-
deoxyuridine 5′-monophosphate (FdUMP) and 5-fluorouridine 
triphosphate (FUTP). 
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Half- life                45-60 mins. 
Pharmacogenetics Dihydro pyrimidine dehydrogenase (DPD) deficiency may 
lead to significant toxicity. 
  
Toxicities Hand foot syndrome, Diarrhea, Mucositis, Nausea, Fatigue, 
Bone marrow toxicity (less common), Angina like chest pain 
(rare) 
Uses Colorectal cancer 
Gastric cancer 
Breast cancer 
Esophageal cancer 
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POLYMER PROFILE 
Polymer Chitosan 
Non proprietary name         BP : chitosan Hcl  
PhEur: chitosanihydrochloridum 
Synonym 2-amino-2-deoxy-(1,4)-b-d-glucopyranan; deacetylated chitin; 
deacetyl chitin; b-1,4–poly–D–glucosamine; poly-D-
glucosamine; poly-(1,4)-b-D-glucopyranosamine. 
Chemical name                   Poly-b-(1,4)-2-Amino-2-deoxy-D-glucose. 
Molecular formula              C56H103N9O39 
Molecular weight                1526.464 g/mol 
Structure                             
 
Description                         Chitosan is a linear polysaccharide composed of randomly 
distributed β-(1-4)-linked D–glucosamine (deacetylated unit) 
and N-acetyl-D-glucosamine (acetylated unit). It is made by 
treating the chitin shells of shrimp and other crustaceans with 
an alkaline substance like sodium hydroxide. Chitosan chitin 
are polysaccharide polymers containing more than 5000 
glucosamine and acetyl glucosamine units, respectively and 
molecular weights are over one million daltons. Chitosan 
occurs as odourless, white creamy powder or flakes. Fibre 
formation is quite common during precipitation and chitosan 
may look like cotton. Chitosan is obtained by the alkaline 
deactivation of chitin. 
Functional category           Coating agent, disintegrant, film forming agent, mucoadhesive, 
tablet binder, viscosity increasing agent. 
Stability and storage  Chitosan powder is a stable material at room temperature, 
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conditions 
 
although it is hygroscopic after drying. Chitosan should be 
stored in a tightly closed container in a cool dry place. The 
phEur 2005 specifies that chitosan should be stored at a 
temperature of 2-8˚c. 
Incompatibilities              Chitosan is incompatible with strong oxidizing agents. 
 
Safety Chitosan is being investigated widely for use as an excipient in 
oral and other pharmaceutical formulations. It is also used in 
cosmetics. Chitosan is generally regarded as a nontoxic and 
non-irritant material. It is biocompatible with both healthy and 
infected skin. Chitosan has been shown to be biodegradable. 
Applications in 
pharmaceutical formulation 
Chitosan is used in cosmetics and is under investigation for use 
in a number of formulations. The suitability and performance 
of chitosan as a component of pharmaceutical formulation for 
drug delivery applications has been investigated in numerous 
studies. These include controlled drug delivery applications 
use as a component of mucoadhesive dosage forms, rapid 
release dosage forms improved peptide delivery, colonic drug 
delivery systems, and use for gene delivery. Chitosan has been 
processed into several pharmaceutical forms including gels, 
films, beads, microspheres, tablets and coatings for liposomes. 
Furthermore, chitosan may be processed into drug delivery 
systems using several techniques including spray drying, 
coacervation, direct compression and conventional granulation 
processes. 
Solubility   Sparingly soluble in water, practically insoluble in ethanol 
(95%) other organic solvents, neutral or alkali solutions at pH 
above approximately 6.5 chitosan dissolve readily in dilute and 
concentrated solutions of most organic acids and to some 
extent in mineral inorganic acids (except phosphoric and 
sulphuric acids). The higher the ionic strength, the lower the 
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solubility as a result of a salting out effect, which leads to the 
precipitation of chitosan in solution. Addition of an electrolyte 
reduces this effect and the molecule possesses a more random, 
coil-like conformation. 
Acidity or alkalinity pH=4.0-6.0 (1%W\V aqueous solution) 
Density 1.35-1.40 g cm
-3 
Glass transition 
temperature 
203˚C 
Moisture content Chitosan adsorbs moisture from the atmosphere, the amount of 
water adsorbed depending upon the initial moisture content 
and the temperature and relative humidity of the surrounding 
air. 
Particle size distribution ˂30 mins. 
Viscosity A wide range of viscous types is commercially available 
owing to its high molecular weight and linear, unbranched 
structure, chitosan is an excellent viscosity enhancing agent in 
an acidic environment. The viscosity of chitosan solutions 
increases with increasing chitosan concentration, decreasing 
temperature, and increasing degree of deacetylation. 
Uses Chitosan has a number of commercial and possible biomedical 
uses. It can be used in agriculture as a seed treatment and bio 
pesticide, helping plants to fight off fungal infections. In 
winemaking, it can be used as a fining agent, also helping to 
prevent spoilage. In industry, it can be used in a self-healing 
polyurethane paint coating. In medicine, it may be useful in 
bandages to reduce bleeding and as an antibacterial agent; it 
can also be used to help deliver drugs through the skin.                 
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EXCIPIENT PROFILE 
Excipient Acetic acid 
Nonproprietary name BP : Glacial acetic acid 
Synonyms Acidumaceticumglaciale, E260, Ethanoic acid, ethylic acid, 
methane carboxylic acid, Vinegar acid. 
Chemical name and CAS 
number 
Ethanolic acid [64-19-7] 
Molecular formula C2H2O2 
Molecular weight 60.05 
Structure CH3CH2OH 
Function Acidifying agent 
Description Glacial acetic acid occurs as a crystalline mass or a clear, 
colorless volatile solution with a pungent odour. 
Application It is used in pharmaceutical products as a buffer system 
when combined with an acetate salt such as sodium acetate. 
Boiling point 118˚C 
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Dissociation constant pKa = 4.76 
Melting point 17˚C 
Refractive index 1.3718 
Specific gravity 1.045 
Solubility Miscible with ethanol, ether, glycerin, water and other fixed 
and volatile oils. 
Storage It should be stored in an air tight container in a cool, dry 
place. 
Incompatibilities Acetic acid reacts with alkaline substances. 
Related substances Glacial acetic acid, dilute acetic acid, artificial vinegar. 
Method of manufacture Acetic acid is usually made by one of three routes: 
acetaldehyde oxidation, involving direct air or oxygen 
oxidation of liquid acetaldehyde in the presence of 
manganese acetate, cobalt acetate or copper acetate; liquid – 
phase oxidation of butane or naphtha; methanol 
carboxylation using a variety of techniques. 
Handling precautions Acetic acid, practically glacial acetic acid, can cause burns 
on contact with the skin, eyes, and mucous membranes. 
Protective clothing, eye protection are recommended. 
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Excipient Tri polyphosphate 
IUPAC name Penta sodium triphosphate 
Other names Sodium tri polyphosphate, polygon 
Structure 
 
CAS number 7758-29-4 
Molecular formula Na5P3O10 
Molecular weight 367.864 g/mol 
Appearance White powder. 
 
Density 2.52 g/cm
3 
Melting point 622˚C 
Solubility It dissolves in water. 
Use Chelating agent. 
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Excipient Calcium chloride 
Nonproprietary names BP: Calcium chloride dihydrate 
Calcium chloride hexahydrate 
JP: Calcium chloride hydrate 
USP-NF: Calcium chloride 
Synonyms Calcium chloridum di hydricum, Calcii chloridum 
hexa hydricum 
Chemical name and CAS number Calcium chloride anhydrous[10043-52-4] 
Calcium chloride dihydrate[10035-04-8] 
Calcium chloride hexahydrate[7774-34-7] 
Molecular formula and molecular 
weight 
Cacl2            -   110.98 (for anhydrous) 
Cacl2.2H2O  -   147.0 (for dihydrate) 
Cacl2.6H2O  -   219.1 (for hexahydrate) 
Functions Antimicrobial preservative, therapeutic agent, water-
absorbing agent. 
Description Calcium chloride occurs as a white or colorless 
crystalline powder, granules, or crystalline mass, and 
is hygroscopic. 
Application It is an excipient relates to its dehydrating properties 
and, therefore, it has been used as an antimicrobial 
preservative, as a desicant, and as an astringent in eye 
lotions. 
Boiling point >1600˚C (anhydrous) 
Density 0.835 g/cm
3 
(dihydrate) 
Melting point 772˚C (anhydrous) 
176˚C (dihydrate) 
30˚C (hexahydrate) 
Solubility Freely soluble in water and ethanol (95%), insoluble 
in diethyl ether. 
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Stability Calcium chloride is chemically stable; however, it 
should be protected from moisture. 
Storage Store in airtight containers in a cool, dry place. 
Incompatibilities It is incompatible with soluble carbonates, 
phosphates, sulfates and tartarates. 
Method of manufacture It is a byproduct from the Solvay process. 
Handling precautions Calcium chloride is irritating to eyes, the respiratory 
system, and skin. Gloves, eye protection, respirator 
and other protective clothing should be worn. 
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Polymer Carbopol 
Nonproprietary names BP: Carbomers 
PhEur: Carbomers 
USP-NF: Carbomer 
Synonyms Acrypol, Acritamer, Acrylic acid polymer, Carbomera, 
Carbopol, Carboxy polymethylene, Polyacrylic acid, 
Carboxyvinyl polymer, Pemulen, Carbomer 
Chemical Name Carbomer  [9003-01-4] 
CAS Number Alternative CAS registry numbers have been used for 
carbomer 934 [9007-16-3], 940 [9007-17-4], and 941 
[9062-04-08]. The CAS registry number [9007-20-9] has 
also been used for carbomer 
IUPAC Name prop-2-enoic acid 
Structure 
 
Molecular formula C3H4O2 CH2=CHCOOH 
Molecular weight 72.063 g/mol 
Description Carbomers are white-coloured, fluffy, acidic, 
hygroscopic powders with a characteristic slight odour. 
A granular carbomer is also available. 
Functions Bioadhesive material, controlled release agent, 
emulsifying agent, emulsion stabilizer, rheology 
modifier, stabilizing agent, suspending agent, tablet 
binder 
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Applications Carbomers are used in liquid or semisolid pharmaceutical 
formulations as rheology modifiers. Formulations 
include creams, gels, lotions and ointments for use in 
ophthalmic, rectal, topical and vaginal preparations. It 
may used in oral preparations, in suspensions, capsules 
or tablets. 
Density Bulk:0.2g/cm
3 
(powder), 0.4g/cm
3 
(granular) 
Tapped:0.3g/cm
3
(powder),0.4g/cm
3 
(granular) 
Dissociation constant pKa=6.0±0.5 
Glass transition temperature 100-105˚C 
Melting point Decomposition occurs within 30 minutes at 260˚C 
Moisture content Typical water content is up to 2%w/w. However, 
carbomers are hygroscopic and typical equilibrium 
moisture content at 25˚C and 50% relative humidity is 8-
10%w/w. The moisture content of a carbomer does not 
affect its thickening efficiency, but an increase in the 
moisture content makes the carbomer more difficult to 
handle because it is less readily dispersed. 
Particle size distribution Primary particles average about 0.2 µm in diameter. The 
flocculated powder particles average 2-7 µm in diameter 
and cannot be broken down into the primary particles. A 
granular carbomer has a particle size in the range 150-
425 µm. 
Log P 0.35 
Solubility Swellable in water and glycerin and, after neutralization, 
in ethanol(95%). Carbomers do not dissolve but merely 
swell to a remarkable extent, since they are three-
dimensionally cross linked microgels. 
Specific gravity 1.41 
Viscosity 
 
Carbomers disperse in water to form acidic colloidal 
dispersions that, when neutralized, produce highly 
viscous gels. Neutralized aqueous gels are more viscous 
at pH 6-11.The viscosity is considerably reduced at pH 
values less than 3 or greater than 12 or in the presence of 
strong electrolytes. 
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Stability  Carbomers are stable, hygroscopic materials that may be 
heated at temperatures below 104˚C for up to 2 hours 
without affecting their thickening efficiency. 
Storage  Carbomer powder should be stored in an airtight, 
corrosion resistant container and protected from 
moisture. The use of glass, plastic, or resin-lined 
containers is recommended for the storage of 
formulations containing carbomer. 
Incompatibilities Carbomers are discolored by resorcinol and are 
incompatible with phenol, cationic polymers, strong 
acids, and high levels of electrolytes. 
Method of manufacture Carbomers are synthetic, high molecular weight, 
crosslinked polymers of acrylic acid. These acrylic acid 
polymers are cross linked with allyl sucrose or allyl penta 
erythritol.. 
Related substance Polycarbophil 
Handling precautions Excessive dust generation should be minimized to avoid 
the risk of explosion. Carbomer dust is irritating to the 
eyes, mucous membranes and respiratory tract. In the 
event of eye contact with carbomer dust, saline should be 
used for irrigation purposes. Gloves, eye protection, and 
a dust respirator are recommended during handling. 
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Polymer                 Cellulose acetate phthalate 
Nonproprietary names BP:Cellacefate 
JP:Cellacefate 
PhEur:Cellulose Acetate Phthalate 
USP-NF:Cellacefate 
Molecular weight 80,000-1,40,000 
Synonyms Cellacefate; CAP; Celacefato; Cellacefato; Cellacefatum; 
Cellulose acetate hydrogen phthalate; cellulose acetate 
hydrogen 1,2- benzenedicarboxylate; Cellulose Acetate 
Monophthalate; Cellulose Acetylphthalate; Cellulose 
Acetophthalate; Cellulose acetate phthalate; HPMCP; 
Hypromellose Phthalate; Acetyl phthalyl cellulose;  
Cellacephate; Cellulose; Cellulose acetate monophthalate; 
Cellulose acetate phthalate; Cellulose aceto phthalate; Cellulose 
acetyl phthalate; Cellulosum 
Method of Manufacture Cellulose acetate phthalate is produced by reacting the partial 
acetate ester of cellulose with phthalic anhydride in the 
presence of a tertiary organic base such as pyridine, or a strong 
acid such as sulfuric acid. 
Solubility Soluble in most organic solvents, Insolube in hot water, alcohol 
Stability Stable under ordinary conditions. 
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Storage Cellulose acetate phthalate is stable if stored in a well-closed 
container in a cool, dry place. 
Appearance white to off-white powder or flakes 
Viscosity A 15%w/w solution in acetone with a moisture content of 0.4%. 
This is a good coating solution with a honey-like consistency, 
but the viscosity is influenced by the purity of the solvent. 
Melting point 192°C. Glass transition temperature is 160–170°C. 
Chemical name Cellulose, acetate, 1,2-benzenedicarboxylate 
CAS Number 9004-38-0 
Structure 
 
Description Cellulose acetate phthalate occurs as a hygroscopic, white to 
off-white, free-flowing powder, granule, or flake. It is tasteless 
and odorless, or might have a slight odor of acetic acid. 
Functions Coating agent; microencapsulating agent; tablet and capsule 
binder 
                                                                                            EXCIPIENT PROFILE 
 
DEPARTMENT OF PHARMACEUTICS, PSG COLLEGE OF PHARMACY Page65 
 
Density Density (bulk) – 0.260 g/cm3  
Density (tapped) -0.266 g/cm3 
Incompatibilities Cellulose acetate phthalate is incompatible with ferrous sulfate, 
ferric chloride, silver nitrate, sodium citrate, aluminum sulfate, 
calcium chloride, mercuric chloride, barium nitrate, basic lead 
acetate, and strong oxidizing agents such as strong alkalis and 
acids. 
Applications Cellulose acetate phthalate (CAP) is used as an enteric film 
coating material, or as a matrix binder for tablets and capsules.  
Cellulose acetate phthalate is commonly applied to solid-dosage 
forms either by coating from organic or aqueous solvent 
systems or by direct compression. The addition of plasticizers 
improves the water resistance of this coating material, and 
formulations using such plasticizers are more effective than 
when cellulose acetate phthalate is used alone. It is also used in 
combination with other coating agents such as ethyl cellulose, 
in drug controlled-release preparations. 
Related Substances Cellulose acetate, hypromellose phthalate, polyvinyl acetate 
phthalate. 
Safety Cellulose acetate phthalate is widely used in oral 
pharmaceutical products and is generally regarded as a nontoxic 
material, free of adverse effects. However, it may be irritant to 
the eyes, mucous membranes, and upper respiratory tract. 
Handling precautions Observe normal precautions appropriate to the circumstances 
and quantity of material handled. Eye protection and gloves are 
recommended. 
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Excipient Magnesium stearate 
Synonyms Dibasic magnesium stearate, Magnesium distearate, 
Magnesiistearas, Magnesium octadecanoate, Octadecanoic 
acid, Magnesium salt, Stearic acid, Synpro 90 
Chemical name Octadecanoic acid magnesium salt 
CAS Number [557-04-0] 
Molecular formula [CH3(CH2)16COO]2Mg 
Molecular weight 591.24 
Structure 
 
Functions Tablet and capsule lubricant 
Description Magnesium stearate is a very fine, light white, precipitated 
or milled, impalpable powder of low bulk density, having a 
faint odour of stearic acid and a characteristic taste.The 
powder is greasy to the touch and readily adheres to the 
skin. 
Application Magnesium stearate is widely used in cosmetics, foods, and 
pharmaceutical formulations. It is primarily used as a 
lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0%w/w. It is also used 
in barrier creams. 
Density Bulk:0.159g/cm
3
 
Tapped:0.286g/cm
3
 
True:1.092g/cm
3
 
Flowability Poorly flowing, Cohesive powder 
Melting point 117-150˚C 
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Solubility Practically insoluble in ethanol, ethanol (95%), ether and 
water, slightly soluble in warm benzene and warm ethanol 
(95%) 
Specific surface area 1.6-14.8m
2
/g 
Stability It is stable 
Storage It should be stored in a well-closed container in a cool, dry 
place. 
Related Compounds Calcium stearate, magnesium aluminium silicate, stearic 
acid, zincs stearate. 
Incompatibilities Incompatible with strong acids, alkalis, and iron salts. 
Avoid mixing with strong oxidizing materials. Magnesium 
stearate cannot be used in products containing aspirin, some 
vitamins, and most alkaloidal salts. 
Method of manufacture Magnesium stearate is prepared either by the interaction of 
aqueous solutions of magnesium chloride with sodium 
stearate or by the interaction of magnesium oxide, 
hydroxide, or carbonate with stearic acid at elevated 
temperatures. 
Handling precautions Eye protection and gloves are recommended. Excessive 
inhalation of magnesium stearate dust may cause upper 
respiratory tract discomfort, coughing, and choking. 
Magneisum stearate should be handled in a well-ventilated 
environment. 
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Excipient Talc 
Synonyms Altalc, Hydrous magnesium calcium silicate, Hydrous 
magnesium silicate, Imperial, Magnesium hydrogen 
metasilicate, Magsil Star, Powdered talc, Purified French 
chalk, Purtalc, Soapstone, Steatite 
Chemical name Talc 
CAS number [14807-96-6] 
Molecular formula Mg6(Si2O5)4(OH)4 
Molecular weight It may contain small, variable amounts of aluminium silicate 
and iron. 
Functions Anticaking agent, glidant, tablet and capsule diluent, tablet and 
capsule lubricant 
Description Talc is a very fine, white to greyish-white, odorless, 
impalpable, crystalline powder. It adheres readily to the skin 
and is soft to the touch and free from grittiness. 
Application Talc was once widely used in oral solid dosage formulations as 
a lubricant and diluent. 
Acidity/Alkalinity pH=7-10 for a 20%w/v aqueous dispersion. 
Moisture content Talc absorbs insignificant amounts of water at 25˚C and 
relative humidities up tp about 90%. 
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Particle size distribution Varies with the source and grade of material. Two typical 
grades are ≥99% through a 74µm (#200 mesh) or ≥99% 
through a 44µm (#325mesh). 
Refractive index 1.54-1.59 
Solubility Practically insoluble in dilute acids and alkalis, organic 
solvents and water. 
Specific gravity 2.7-2.8 
Specific surface area 2.41-2.42m
2
/g 
Stability Talc is a stable material and may be sterilized by heating at 
160˚C for not less than 1 hour. It may also be sterilized by 
exposure to ethylene oxide or gamma irradiation 
Storage Talc should be stored in a well-closed container in a cool, dry 
place. 
Incmpatibilities Incompatible with quaternary ammonium compounds. 
Related substances Bectonite, Magnesium aluminum silicate, Magnesium silicate, 
Magnesium trisilicate. 
Method of manufacture Talc is a naturally occurring hydro poly silicate mineral. It is 
pulverized before being subjected to flotation processes to 
remove various impurities such as asbestos; carbon; dolomite; 
iron oxide; and various other magnesium and carbonate 
minerals. Following this process, talc is finely powdered, 
treated with dilute hydrochloric acid, washed with water, and 
then dried. 
Handling precautions Talc is irritant if inhaled and prolonged excessive exposure 
may cause pneumoconiosis. Eye protection, gloves and a 
respirator are recommended. 
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MATERIALS AND EQUIPMENTS 
    Table 3: LIST OF CHEMICALS USED 
S.NO INGREDIENTS VENDER 
1. Capecitabine Gift sample 
2. Chitosan Sigma Aldrich Chemie USA 
3. Tri poly phosphate Loba Chemie Ltd., Mumbai 
4. Calcium chloride Loba Chemie Ltd., Mumbai 
5. Acetic acid Thermo Fisher Scientific India       
Pvt. LTD 
6. Carbopol Himedia Laboratories 
7. Cellulose acetate phthalate Sigma Aldrich Chemie USA 
8.  Ethanol JEBSEN & JESSEN GmbH & CO  
Germany 
9. Acetone S D Fine – Chem Limited 
10. Sodium hydroxide Merch 
11. Potassium dihydrogen phosphate Himedia Laboratories 
 
 
                                                               MATERIALS & EQUIPMENTS 
 
DEPARTMENT OF PHARMACEUTICS, PSG COLLEGE OF PHARMACY Page 71 
 
   Table 4: LIST OF EQUIPMENTS USED 
       1. Digital Weighing Balance Shimadzu, AZ 220 
       2. Magnetic Stirrer Remi Equioments Ltd, 1MLH 
       3. Bath Sonicator PCI, ultrasonics 
       4. Centrifuge Remi R-8c Laboratory 
       5. pH meter Systronics, pH system 361 
       6. UV Spectrophotometer UV-1650 Pc Shimadzu 
       7. FT-IR Spectrophotometer Shimadzu 8400 S 
       8. Freeze drier Delvac pumps, MINI LYODEL 225 V 
       9. Zeta sizer Nano ZS90, Malvern 
      10. Hardness Dolphin 
      11. Thickness Dolphin 
      12. Friability INWEKA 
      13. Dissolution test apparatus LABINDIA DS 8000 
      14. Disintegration tester LABINBIA 
      15. Scanning Electron Microscope ZEISS SUPRA 40 
      16. Phase Contrast Microscope Nikkon Eclipse TS – 100 
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PREFORMULATION STUDIES   
MELTING POINT DETERMINATION: 
Digital melting point apparatus is used to determine the melting point of capecitabine by 
capillary method. One end of the capillary tube was sealed with gentle heat using Bunsen burner 
and then the small quantity of pure drug capecitabine was filled into the sealed capillary tube. 
Then this capillary tube with the pure drug was placed in a melting point viewer. The 
temperature at which drug gets melted is taken as melting point of drug. 
DETERMINATION OF λ MAX: 
PREPARATION OF STOCK A: 
The capecitabine stock-A solution was prepared by dissolving 100 mg of drug in 100 ml of water 
to obtain a drug concentration of 1000 mcg/ml. 
PREPARATION OF STOCK B: 
 From the above stock-A, 1 ml were taken and diluted to 100 ml to prepare stock B of 
concentration 10 mcg/ml. 
DETERMINATION OF ANALYTICAL WAVELENGTH: 
To form concentration of 1 mcg/ml, 1ml of stock B was diluted to 10 ml, then the solution was 
scanned using double beam UV visible spectrophotometer in the spectrum mode between the 
wavelength ranges of 200 nm to 400 nm. 
STANDARD CURVE OF CAPECITABINE: 
                        100 mg of drug was weighed and transferred to a 100 ml standard flask, diluted to 
100 ml with phosphate buffer to prepare concentration of 1000 mcg/ml and sonicated for few 
minutes which were the standard stock solution. 1ml of this stock solution was taken and diluted 
with 100ml buffer to obtain concentration at 10 mcg/ml. And this prepared solution was serially 
diluted to get the different concentrations (1, 2, 3, 4, 5, 6, 7, 8, 9, and 10mcg/ml) to determine the 
linearity range. The standard samples were analyzed at 240 nm using UV Spectrophotometer.  
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SOLUBILITY STUDY: 
Solubility of the drug is predicted by dissolving 1 mg of the drug in proportions of 1 ml, 10 ml, 
30 ml and 100 ml of the proposed solvents. So according to the dilution or the dissolving 
property the solubility was predicted by measuring 240 nm by UV-Visible spectroscopy. A test 
for the solubility becomes a test for purity only where a special quantitative test is given in the 
individual monograph and is an official requirement. (IP [2.4.26 Solubility]) 
SOLUBILITY PARAMETERS: 
 Table 5: SOLUBILITY PARAMETERS 
DESCRIPTIVE TERMS PART OF SOLVENT REQUIRED FOR 
PART OF SOLUTE 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 1000 to 10000 
Practically insoluble 10000 or more 
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FT – IR DRUG POLYMER COMPATIBILITY STUDY: 
Infrared spectra of drug and its inclusion complexes were recorded by KBr pellet method using 
Fourier Transform Infrared spectrophotometer. A base line correction was made using dried 
potassium bromide and then spectra of dried mixtures of drug and inclusion complexes with 
potassium bromide were recorded. The samples were prepared by KBr pellet press method; the 
scanning wavelength range was 400-4000 cm-1. 
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        METHODOLOGY 
FORMULATION OF CAPECITABINE NANOPARTICLES: 
                                             Figure 7: IONIC GELATION METHOD  
 
 
 
a) Preparation of chitosan solution: 
Chitosan was weighed and transferred into a glass beaker. To this chitosan, 0.1ml of 
acetic acid and 50ml of water was added and kept for overnight stirring to obtain product 
A. 
b) Preparation of tri polyphosphate solution: 
Tri polyphosphate was added to the distilled water. To this solution, drug solution was 
added and kept for 30 minutes stirring to obtain product B. 
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c) Formulation of capecitabine nanoparticles: 
The product A (chitosan solution) was taken in a beaker and kept for continuous stirring. 
Then the drug solution was taken in an insulin syringe and added drop by drop to the 
chitosan solution. The final solution was mixed with CaCl2. Finally the capecitabine 
nanoparticle was prepared. 
CHARACTERIZATION OF CAPECITABINE NANOSUSPENSION: 
a) Determination of particle size by photon correlation spectroscopy: 
The average mean diameters and size distribution of nanosuspension was found out by 
photon correlation spectroscopy using Zetasizer (nano ZS90, Malvern Instruments) at 
25˚C.The samples were kept in polystyrene cuvette and the readings were find out at a 
fixed angle 
b) Determination of zeta potential: 
The electrophoretic mobility (zeta potential) measurements of nanosuspension were made 
using Zetasizer (Nano ZS90, Malvern Instruments). The samples were placed in a 
polystyrene cuvette (at 25˚C) and Zeta dip cell was used to measure the potential. 
c) Lyophilization technique: 
Freeze drying was performed to convert the aqueous solution of drug loaded 
nanoparticles into powder. The selected formulations were kept in well closed containers 
and allowed to freeze under -80˚C for 4 hours. Then the formulation was freeze dried 
using LYODOL freeze dryer at -40˚C and -1.12 mbar pressure for a period of 72 hours. 
CHARACTERIZATION OF CAPECITABINE NANOPARTICLE: 
SCANNING ELECTRON MICROSCOPY: (SEM) 
The shape and surface characteristics was observed by scanning electron microscopy (SEM). 
The morphology of the lyophilized capecitabine loaded nanoparticles was characterized by using 
field emission scanning electron microscopy (Zeiss Supra 40 apparatus Germini column, 
Germany) operated at 5 KV accelerating voltage. Scanning electron microscopy is a type of 
electron microscopy that images the surface of solid specimen by using focused beam of high 
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energy electrons. The scanning process and image formation in SEM depends on signal produced 
by elastic and inelastic interactions between high energy electron beam and specimen surface. 
The particle size analysis of lyophilized nanoparticles was carried out to confirm the Nano size 
of the formulation. The samples were lightly sprinkled on a double sided adhesive tape stuck to 
an aluminium stub and the stubs were placed in scanning electron microscope chamber. 
PHASE CONTRAST MICROSCOPY: 
The samples was taken on glass slide and observed under Nikon Leica inverted phase contrast 
microscope. Images were taken on computer monitor using Leica software and shape of the 
particles was observed. 
DRUG CONTENT IN THE FORMULATION: 
                            22mg product was dissolved in 100ml of distilled water. From this 1ml was 
taken and made up to 10ml and absorbance was taken at 240nm using UV spectrophotometer. 
From this the required amount of nano formulation to be made into tablet and it is being 
calculated. 
ENTRAPMENT EFFICIENCY: 
2ml of the formulation was taken and ultra-centrifuged at 13,000rpm at 4˚C for 30minutes using 
eppendorf centrifuge. The supernatant was recovered using micro pipette. 
 Encapsulation efficiency (%) =   Total amount of drug – Free drug   X 100 
          Total amount of drug 
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FORMULATION OF CAPECITABINE LOADED CHITOSAN NANOPARTICLES: 
                      Table 6: FORMULATION OF CAPECITABINE NANOPARTICLES 
Formulation Chitosan 
(mg) 
Acetic 
acid 
(ml) 
Water 
(ml) 
Tri polyphosphate 
(mg) 
Drug 
(mg) 
Water 
(ml) 
Calcium 
chloride 
(mg) 
1 200 1 100 3.5 150 10 - 
2 200 1 100 3.5 150 10 50 
3 200 1 100 7.2 150 10 - 
4 200 1 100 7.2 150 10 50 
5 200 1 100 7.2 150 50 - 
6 200 1 100 7.2 150 50 50 
7 100 0.5 50 7.2 50 50 - 
8 100 0.5 50 7.2 50 50 50 
9 100 0.5 50 14.5 50 50 - 
10 100 0.5 50 14.5 50 50 50 
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PREPARATION OF TABLETS: 
Capecitabine tablets were prepared by direct compression method in which active ingredients 
and excipients are present. To the formulation product magnesium stearate and talc were added 
and the tablets were compressed. The formula for preparation of tablets was listed below. 
 Table 7: PREPARATION OF TABLETS 
Ingredients Amount per tablet(mg) 
Formulation 645 
Magnesium stearate (2%) 12.9 
Talc (1%) 6.45 
Total 664.35 
 
EVALUATION OF TABLETS: 
ANGLE OF REPOSE: 
The method used to find the angle of repose is to pour the powder a conical on a level, flat 
surface and measure the included angle with the horizontal.    
                                       θ = Tan -1 (h/r)  
Where, θ = Angle of repose, h = Height of the powder cone, r = Radius of the powder cone. 
BULK DENSITY AND TAPPED DENSITY OF GRANULES: 
The bulk density and tapped bulk density were determined and calculated by the following 
formulas.  
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BD = weight of the powder / initial volume  
TD = weight of the powder / final volume   
COMPRESSIBILITY OF GRANULES: 
The compressibility index was determined by Carr‟s compressibility index and Hausner‟s ratio. 
 Carr‟s index = TD – BD X 100 / BD 
 Hausner‟s ratio = TD / BD 
WEIGHT VARIATION TEST: 
20 tablets of formulation were weighed using electronic balance and the test was performed 
according to the USP official limits. Percentage deviation of tablet is calculated in the table 
below. 
                %Maximum positive deviation = [WH -
 
 
] ˟100 
                %Minimum negative deviation = [A-
  
 
] ˟100 
Where, 
WH - Highest weight of tablet in mg 
WL - Lowest weight of tablet in mg 
 A - Average weight of tablet in mg 
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IP/BP AND USP LIMITS OF WEIGHT VARIATION TEST: 
                                    Table 8: LIMITS OF WEIGHT VARATION 
               IP/BP              USP LIMIT 
80mg or less 130mg or less ±10% 
More than 80mg and less than 
250mg 
130mg to 324mg ±7.5% 
250mg or more More than 324mg ±5% 
 
TABLET THICKNESS: 
Thickness of tablet was important for uniformity of tablet size. Tablets were selected and 
thickness was measured by using vernier – caliper scale, which permits accurate measurement. 
HARDNESS OF TABLETS: 
Hardness of tablet is the indication of its strength against resistance of tablet to capping, abrasion 
or breakage under conditions of storage, temperature and handling before usage. Hardness of 
tablets was determined using Pfizer hardness tester and is measured in kg/cm
2
. 
FRIABILITY TEST: 
The friability of the tablets was determined by Roche friabilator. Accurately weigh the tablets 
and place them in the friabilator. These tablets were subjected to friability at 25rpm for 4 mins 
(100 rotations). Initial and final weights of the tablets were noted and calculated as per following 
formula,                % Friability = Initial weight – Final weight x 100 
                                                                Initial weight 
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DISINTEGRATION TEST: 
Disintegration test for the prepared tablets were performed using Basket-rack assembly. One 
tablet was placed in each of six tubes of the basket and test was performed using different buffers 
as the immersion fluid maintained at 37± 2˚C. Time for complete disintegration of all six tablets 
was noted. 
DISSOLUTION TEST: 
Dissolution studies were carried out by using USP-II dissolution test apparatus using paddle 
method. For dissolution testing tablets, immersed at a time, and evaluated in pH 1.2, 7.4, and 6.8 
dissolution media. To match the changes in pH along the GI tract, three dissolution media with 
pH 1.2, 7.4 and 6.8 were used sequentially. These three media represents the stomach, proximal 
part of the small intestine and terminal ileum respectively. When performing studies, the pH 1.2 
medium was first used for 2 h, and then replaced with the fresh pH 7.4 phosphate buffers. After 
3-4 hour the medium was again replaced with fresh pH 6.8 dissolution medium. 
CELL LINE STUDIES: 
Cell culture: 
 The colorectal cancer cell lines (HT 29) were purchased from the National Center for 
Cell Sciences (NCCS), Pune, India. The cells were maintained in their respective modified 
eagles medium (MEM) supplemented with 2mM l-glutamine and balanced salt solution (BSS) 
adjusted to contain 1.5 g/L Na2CO3, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 
2 mM l-glutamine, 1.5 g/L glucose, 10 mM (4-(2-hydroxyethyl)-1-piperazineethane sulfonic 
acid) (HEPES) and 10% fetal bovine serum (GIBCO, USA). Penicillin and streptomycin (100 
IU/100 µg) were adjusted to 1mL/L. The cells were maintained at 37◦C with 5% CO2 in a 
humidified CO2 incubator. 
Evaluation of cytotoxicity: 
 The inhibitory concentration (IC50) value was evaluated using an MTT [3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Cells were grown 
(1×104cells/well) in a 96-well plate for 48 h in to 75% confluence. The medium was replaced 
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with fresh medium containing serially diluted compounds (Samples), and the cells were further 
incubated for up to 48 h. The culture medium was removed, and 100µL of the MTT [3-(4,5-
dimethylthiozol-2-yl)-3,5-diphenyl tetrazolium bromide] (Hi-Media) solution was added to each 
well and incubated at 37◦C for 4 h. After removal of the supernatant, 50 µL of DMSO was added 
to each of the wells and incubated for 10 min to solubilize the formazan crystals. The optical 
density was measured at 620 nm in an ELISA multi well plate reader (Thermo Multiskan EX, 
USA). The OD value was used to calculate the percentage of viability using the following 
formula. 
OD value of experimental sample  
Formula: % of viability = ___________________________   × 100 
OD value of experimental control   
DRUG RELEASE STUDIES: 
Mathematical model plays important role in the prediction of mechanism of drug release and also 
provides more general guidelines for development of other system. To describe the drug release 
rate from different drug delivery system a large numbers of models were developed. Some of 
important models are,  
 Zero order kinetic model 
 First order kinetic model   
 Higuchi model  
 Korsmeyer-peppas model  
        The model that best fits the release data is selected based on the correlation coefficient 
value in various models. The model that gives high R
2
 value is considered as the best fit of the 
release data. 
Zero order release: 
                 It describes the systems where the drug release rate is independent of its concentration 
of the dissolved substance. 
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                Qt =Q0 + K0t 
     Where, 
               Q0 = Initial amount of drug 
               Qt = Cumulative amount of drug release at time “t” 
               Ko = Zero order release constant 
                t   = Time in hours 
First order release: 
The drug release rate depends on its concentration. 
                    Log Qt = Log Qo + Kt/2.303 
         Where, 
                  Qo = Initial amount of drug 
                  Qt  = Cumulative amount of drug release at time “t” 
                   K = First order release constant 
                   t   = Time in hours 
Higuchi release: 
The Higuchi equation suggests that the drug release by diffusion. 
Where, 
                 Q  = Cumulative amount of drug release at time “t” 
                 KH = Higuchi constant 
                    t = Time in hours 
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Korsmeyer – peppas equation: 
                Korsmeyar – peppas equation is 
                     F = (Mt/M) = Km t
n 
           Where, 
                   F = Fraction of drug released at time„t‟ 
                  Mt = Amount of drug released at time„t‟ 
                  M = Total amount of drug in dosage form 
                  Km = Kinetic constant 
                    n = Diffusion or release exponent 
                    t = Time in hours 
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                                             RESULT AND DISCUSSION 
PREFORMULATION STUDIES:  
Melting point: 
Melting point was found to be 121˚ C which confirms the drug capecitabine. 
Solubility: 
Solubility of capecitabine in different solvent was carried out and found that 
 Soluble in water ( 26 mg/ml) 
 Slightly soluble in ethanol (207 mg/ml) 
Determination of lamda max of Capecitabine: 
The prepared stock solution of Capecitabine was scanned in UV – Visible spectrophotometer 
from 200-400 nm. 
Figure 8: DETERMINATION OF LAMDA MAX BY UV SPECTROSCOPY 
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The maximum wavelength occurs at 239.40 nm and hence 240 nm was selected as 
maximum absorbance for further studies. 
Calibration curve of Capecitabine by UV Spectrophotometer: 
Standard curve of capecitabine was plotted by using UV spectrophotometer and the 
absorbance was noted as 240 nm. A series of concentrations of solutions ranging from 1-10 
mcg/ml were prepared and the corresponding absorbance was noted. The absorbance values 
corresponding to the concentration were shown in table and the regression value was found to be 
0.995 from the graph. 
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Table 9:  STANDARD CURVE DATA OF CAPECITABINE 
Concentration 
(mcg/ml) 
Absorbance 
(240 nm) 
1 0.116 
2 0.180 
3 0.262 
4 0.360 
5 0.467 
6 0.549 
7 0.630 
8 0.751 
9 0.789 
10 0.875 
 
Figure 9: STANDARD CURVE OF CAPECITABINE 
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FT – IR SPECTROSCOPY: 
Figure 10: FT-IR OF CAPECITABINE 
 
 
                                   Table 10:  FT-IR DATA OF CAPECITABINE 
S. No Wave Number cm
-1
 Assignment 
1 3184 O-H stretching 
2 1552 C=O stretching 
3 1720 C-F stretching 
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Figure 11: FT-IR OF CHITOSAN 
 
 
                                     Table 11:  FT-IR DATA OF CHITOSAN 
S. No Wave Number cm
-1
 Assignment 
1 1321 Carbonyl stretching of secondary amide 
2 1152 N-H stretching of amine 
3 1079 Ether bonds 
4 1030,895 Secondary hydroxyl groups, 
characteristic peak of CH-OH and cyclic 
alcohols, C-0 stretching. 
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Figure 12: FT-IR OF CALCIUM CHLORIDE 
 
 
                          Table 12: FT-IR DATA OF CALCIUM CHLORIDE 
S. No Wave Number cm
-1 
Assignment 
1 3437 C-O-H stretching 
2 3429 Asymmetric stretching peak of 
calcium salt group 
3 602.9 Asymmetric stretching 
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Figure 13: FT-IR OF TRI POLYPHOSPHATE 
 
      Table 13: FT-IR DATA OF TRIPOLYPHOSPHATE 
S. No Wave Number cm
-1 
Assignment 
1 1226 Secondary amide group stretching 
2 1094 Symmetric stretching peak of C=C 
group 
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Figure 14: FT-IR OF MAGNESIUM STEARATE 
 
 
Table 14: FT-IR DATA OF MAGNESIUM STEARATE 
S. No Wave Number cm
-1
 Assignment 
1 2956 Symmetric C-H stretching 
2 1550 C=O stretching 
3 966 C-CH3 bending 
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Figure 15: FT-IR OF TALC 
 
 
 
 
 
 
 
 
 
 
 
Table 15: FT-IR DATA OF TALC 
S. No Wave Number cm
-
1 Assignment 
1 2919 C-H stretching 
2 2447 N-H stretching 
3 1028 C-N bending 
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Figure 16: FT-IR OF PHYSICAL MIXTURE OF CAPECITABINE AND EXCIPIENTS 
 
 
Table 16: FT-IR DATA OF PHYSICAL MIXTURE OF CAPECITABINE AND 
EXCIPIENTS 
S. No Wave Number cm
-1 
Assignment 
1 3196 O-H stretching 
2 1556 C=O stretching 
3 1722 C-F stretching 
4 2910 C-H stretching 
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Drug – excipients compatibility was checked by comparing the IR spectra of pure drug, 
excipients and physical mixture of drug with excipients. No significant changes in the functional 
group between the spectra were observed. This ensured that there was no interaction between 
drug and excipients. 
PREPARATION OF CAPECITABINE NANOPARTICLES: 
Capecitabine nanoparticle was prepared by using chitosan as polymer, Tri polyphosphate 
as cross linking agent and calcium chloride as stabilizer along with solvent of water and acetic 
acid by ionic-gelation technique. 
Figure 17: FORMATION OF NANOPARTICLE 
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PARTICLE SIZE AND ZETA POTENTIAL OF CAPECITABINE 
NANOFORMULATIONS: 
Table 17 
Formulation code Particle size (nm) PDI Zeta potential (mV) 
1 4028 0.617 60.1 
2 1013 0.828 38.4 
3 4057 0.257 60.7 
4 967.4 0.994 36.2 
5 1843 0.992 57.6 
6 804.9 0.860 50.8 
7 2665 1.000 52.7 
8 773.2 0.937 39.5 
9 616.3 0.702 34.2 
10 474.4 0.730 19.5 
 
Formulation 9, 10 was found to be 616.3 nm and 474.4 nm in particle size with zeta potential of 
19.2 mV and 34.2 mV . So F-9, 10 was selected for further studies. 
DETERMINATION OF PARTICLE SIZE AND ZETA POTENTIAL: 
The average mean diameters and size distribution and the electrophoretic mobility (zeta 
potential) measurements of Capecitabine loaded nanoparticles was found out by photon 
correlation spectroscopy were made using Zeta sizer (Nano ZS90, Malvern Instruments) at 25˚C. 
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PARTICLE SIZE AND ZETA POTENTIAL FOR FORMULATION 9:  
                  Figure 18: PARTICLE SIZE OF FORMULATION 9 
 
 
       Figure 19: ZETA POTENTIAL OF FORMULATION 9 
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PATICLE SIZE AND ZETA POTENTIAL FOR FORMULATION 10:  
Figure 20: PARTICLE SIZE OF FORMULATION 10 
              
           
Figure 21: ZETA POTENTIAL OF FORMULATION 10 
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DETERMINATION OF MORPHOLOGY OF THE NANOSUSPENSION BY PHASE 
CONTRAST MICROSCOPY: 
The drug loaded nanosuspension was observed under phase contrast microscopy to study the 
morphology of suspension. 
Figure 22: IMAGE OF PHASE CONTRAST MICROCOPY 
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SCANNING ELECTRON MICROSCOPY OF NANOFORMULATION OF 
CAPECITABINE: 
The surface morphology and size for the selected suspensions was studied using field emission 
scanning electron microscopy (ƩIGMA FE-SEM; Zeiss Supra 40 apparatus Germini column, 
Germany) operated at 5 kV accelerating voltage. The images obtained showed cubic particles. 
     Figure 23: IMAGE OF SCANNING ELECTRON MICROSCOPY 
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FREEZE DRYING (LYOPHILIZATION): 
Freeze drying was performed to convert the nanosuspension into powder. The selected 
formulations were kept in well closed containers and allowed to freeze under -80˚C for 4 hours. 
Then the formulations was freeze dried using LYODOL freeze dryer at -40˚C and -1.12 mbar 
pressure for a period of 72 hours. At the end of 72 hours a drug loaded white powder were 
obtained. 
Figure 24: LYOPHILIZED CAPECITABINE NANOPARTICLES 
       
       
 
 
DRUG CONTENT AND ENTRAPMENT EFFICIENCY OF THE FORMULATION:  
DRUG CONTENT: 
            Amount of drug present in the lyophilized product was found to be 1.3 mg for 
formulation 9 and 5.4 mg for formulation 10, when compare to theoretical yield of 5.11 mg it 
was found that formulation 9 was having only 25.44% and formulation 10 was having 105.67%. 
Therefore formulation 10 was selected for further studies. 
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ENTRAPMENT EFFICIENCY: 
Entrapment efficiency of the desired formulation 10 was determined. 
                     Table 18: ENTRAPMENT EFFICIENCY OF THE FORMULATION 
Formulation Absorbance Concentration(mcg/ml) Amount of drug Entrapment 
efficiency (%) 
10 0.101 3 0.03 96.35±5 
 
PREPARATION OF TABLETS: 
                                Table 19: FORMULA FOR TABLETS 
Ingredients Amount per tablet (mg) 
Nanoformulation 645 
Magnesium stearate (2%) 12.9 
Talc (1%) 6.45 
Total 664.35 
 
Figure 25: IMAGE OF TABLET 
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EVALUATION OF TABLETS: 
PRE COMPRESSION EVALUATION: 
                              Table 20: DATA OF ANGLE OF REPOSE 
Product r (cm) h (cm) Ɵ = tan-1h/r Flow property 
Without 
excipients 
1.5 2 53.12˚ Poor 
With excipients 2.6 2 34.56˚ Good 
 
Table 21:  BULK AND TAPPED DENSITY, CARR’S INDEX AND HAUSNER’S RATIO 
OF FORMULATION 
 Bulk density Tapped density Carr’s index (%) Hausner’s ratio 
Trial 1 0.5  0.58  13.79  1.16  
Trial 2 0.5 0.57 12.28 1.14 
Trial 3 0.42 0.48 12.47 1.14 
Average 0.47±0.046 0.54±0.055 12.84±0.822 1.146±0.011 
 
The bulk density and tapped density ranged from 0.5 and 0.58 respectively. The angle of 
repose and compressibility index (%) ranged from 34.56˚ and 13.79%. According to the 
guideline the angle of repose, compressibility index and hausner’s ratio indicates good flow 
properties if the value of angle of repose (31-35) compressibility index (11-15) and hausner’s 
ratio (1.12-1.18) of the powder mixture. These results show that the powder mixture has good 
flow properties. 
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POST COMPRESSION EVALUATION: 
WEIGHT VARIATION TEST FOR FORMULATION 10: 
                             Table 22: WEIGHT VARIATION DATA OF TABLETS 
S. No Weight of tablet (mg) 
1 658 
2 657.5 
3 661 
4 659 
5 662 
6 661.5 
7 657 
8 658 
9 656 
10 662 
11 660 
12 659 
13 667.5 
14 663 
15 664 
16 662.5 
17 664 
18 670 
19 659 
20 650 
Average weight 660.5 ± 5% 
 
Weight variation test was performed for 20 tablets. All the tablets passed the weight 
variation test as per the pharmacopoeial limit and was within 5% as shown in the table above. 
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FRIABILITY TEST FOR FORMULATION 10: 
                                     Table 23: FRIABILITY TEST DATA OF TABLETS 
Tablets Weight of 10 tablets 
before the test(mg) 
Weight of 10 tablets 
after the test(mg) 
%Friability 
1 658 657 0.15 
2 657.5 656 0.15 
3 661 658 0.3 
4 659 657 0.15 
5 662 659 0.45 
6 661.5 659 0.3 
7 657 655 0.3 
8 658 655 0.15 
9 656 653 0.4 
10 662 658 0.36 
   Average 
weight=0.271 
                                                
Friability test for tablets was carried out and it was passed the friability test as per the 
pharmacopoeial limit and was within 1% as shown in the table. 
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HARDNESS TEST FOR FORMULATION 10: 
                                  Table 24: HARDNESS TEST DATA OF TABLETS 
Trial Hardness (kg/cm
2
) 
Trial 1 5.98 
Trial 2 5.95 
Trial 3 6.00 
Average 5.97 ± 0.025166 
 
The hardness test was performed for the tablets. Then the values were within the limits 
prescribed in the pharmacopoeia as shown in the above table. 
THICKNESS TEST FOR FORMULATION 10: 
                                  Table 25: THICKNESS TEST DATA OF TABLETS 
Trial Thickness (cm) 
Trial 1 0.71 
Trial 2 0.68 
Trial 3 0.61 
Average 0.66 ± 0.051316 
            The thickness test was performed for the tablets and the values were within the limit. 
DISINTEGRATION TEST FOR FORMULATION 10: 
                 Disintegration test was performed for the tablets from formulation using pH 1.2 and 
pH 6.8 as the medium. As the immersion fluid of pH 1.2 the tablets show no evidence of 
disintegration because of the enteric coating of the tablet. Then using the pH 6.8, tablets 
disintegrates within 30 mins. 
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In vitro DRUG RELEASE FOR FORMULATION 10: 
                         Table 26: RELEASE PROFILE OF FORMULATION 
pH Time(mins) Absorbance Concentration 
(mcg/ml) 
Amount of 
drug release 
(mg) 
% drug 
release (%) 
Cumulative 
drug release 
(%) 
1.2 60 0 - - - - 
 120 0 - - - - 
7.4 180 0.027 0.2 1.8 1.2 1.2 
 240 0.046 0.5 4.5 3 3 
 300 0.073 0.8 7.2 4.8 4.8 
6.8 305 0.091 1 9 6 10.8 
 310 0.153 1.7 15.3 10.2 15 
 315 0.245 2.6 23.4 15.6 20.4 
 330 0.398 4.4 39.6 26.4 31.2 
 345 0.474 5.3 47.7 31.8 36.6 
 360 0.590 6.6 59.4 39.6 44.4 
 420 0.752 8.5 76.5 51 55.8 
 480 0.827 9.1 81.9 54.6 59.4 
 
In vitro drug release was performed and calculated. It shows the drug release in three 
different pH buffer solutions. In pH 1.2 (0.1N Hcl)  the drug was not released because of the 
enteric coating layer of the tablet and in pH 7.4 phosphate buffer  it shows the release of 4.8% at 
3 hours. Then in pH 6.8 phosphate buffer the release was 54.6% at 3 hours. Total release was 
found to be 59.4% at 8 hours.  
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Figure 26: DISSOLUTION IMAGE OF FORMULATION 
                         
 
Figure 27: %DRUG RELEASE OF FORMULATION 10 
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DRUG RELEASE KINETICS: 
ZERO ORDER KINETICS OF FORMULATION 10: 
Figure 28: ZERO ORDER RELEASE 
 
 
FIRST ORDER KINETICS OF FORMULATION 10: 
Figure 29: FIRST ORDER RELEASE 
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HIGUCHI RELEASE OF FORMULATION 10: 
Figure 30: HIGUCHI RELEASE 
 
 
KORSMEYER PEPPAS OF FORMULATION 10: 
Figure 31: KORSMEYER PEPPAS RELEASE 
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Table 27: RELEASE KINETICS DATA 
 
Release kinetics model R
2 
values 
Zero order kinetics 0.5909 
First order kinetics 0.5385 
Higuchi 0.3848 
Korsmeyer peppas 0.8620 
n = 2.762 
 
 
Comparing the R
2
 values, korsmeyer peppas gives high R
2
 value. So, this 
korsmeyer peppas kinetics model considered as the best release kinetics. If n>1, this 
model is considered as the super case II transport. 
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CELL LINE STUDIES: 
MTT ASSAY: 
Cytotoxic activity of samples (µg/ml) IC50 
Table 28: DATA OF INHIBITORY CONCENTRATION 
Sample HT-29 (colon carcinoma) 
Drug 46±1.5 
Formulation 28±0.5 
Standard : Doxorubicin 22±0.5 
 
IC50 – Values of respective samples (at 24 hours) 
                                                          OD value of experimental sample 
Formula: % of viability = ___________________________    ×100 
                                                          OD value of experimental control 
%CELL VIABILITY OF CAPECITABINE DRUG SOLUTION AND FORMULATION: 
Figure 32: % CELL VIABILITY OF CAPECITABINE DRUG SOLUTION 
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Figure 33: % CELL VIABILITY OF FORMULATION 10: 
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 PHASE CONTRAST MICROSCOPY OF CAPECITABINE DRUG SOLUTION AND 
FORMULATION: 
Figure 34: PCM OF CAPECITABINE DRUG SOLUTION 
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Figure 35: PCM OF FORMULATION 10 
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FLUORESCENCE MICROSCOPY OF CAPECITABINE DRUG SOLUTION AND 
FORMULATION: 
Figure 36: FLUORESCENCE MICROSCOPY OF CAPECITABINE DRUG SOLUTION 
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Figure 36: FLUORESCENCE MICROSCOPY OF FORMULATION 10 
 
The inhibitory concentration (IC50 ) means the concentration required to reduce the cell 
viability. IC50 of the capecitabine drug solution and formulation was found to be 46 µg/ml and 28 
µg/ml respectively. The standard shows the inhibitory concentration of 22 µg/ml. Based on IC50, 
the formulation showed better cytotoxic activity with decreased cell viability when compared 
with capecitabine drug solution. Cell viability was reduced on increasing concentration of 
formulation and capecitabine drug solution. When compared with control, formulation 10 shows 
better cytotoxic activity than capecitabine drug solution. This was assessed by phase contrast 
microscopy and fluorescence microscopy. 
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 CONCLUSION 
                          The study concludes that the drug capecitabine in nanoparticulate drug delivery 
system of ionic gelation technique yields 474.4 nm nanosize of particles with good zeta potential 
and SEM analysis also confirms the surface morphology of nanoparticles with cubic shape. 
                  The prepared capecitabine nanoparticles were taken along with magnesium 
stearate and talc was taken as excipients for preparation of tablets by direct compression method. 
Evaluation of tablets such as weight variation test, Hardness test, Thickness test, Friability test 
and disintegration test was carried out and shown that the tablets were within the limit. 
              In -vitro dissolution study was performed for tablet and the release showed 
59.4% at end of the 8 hours to target the colon. For release data, drug release kinetics was 
performed such as zero order kinetics, first order kinetics, Higuchi release and Korsmeyer 
peppas model. 
               Further, cell line study was carried out using HT 29 (Colon carcinoma) cells. This 
study confirmed, the formulation showed better cytotoxic activity than capecitabine drug 
solution. 
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